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ABSTRACT
Acute myeloid leukemia (AML) is associated with mutations or chromosomal translocations in genes encoding transcription factors. PU.1 is a transcription factor that is required
for the development of nearly all white blood cell types of the immune system, including B
cells, granulocytes, and monocytes. Mutation of the gene encoding PU.1, SPI1 in humans
and Sfpi1 in mice, is associated with AML. We hypothesized that reduced expression of
PU.1 in Sfpi1BN/BN myeloid cells will result in the development of AML in transplanted
mice due to reduced repression of E2F1, leading to deregulation of the cell cycle. Results
indicate that NOD/SCID/γc-/- mice transplanted with Sfpi1BN/BN splenocytes become sick
with disease resembling AML. Induction of PU.1 expression results in repression of the
cell cycle regulator, E2F1, suggesting PU.1 represses E2F1 in order to enable cell cycle
exit and differentiation. Understanding the pathways controlled by PU.1 can be used in
therapies for the treatment of AML.
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CHAPTER 1: INTRODUCTION
1.1 Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a cancer of the myeloid lineage of white blood
cells. It is a disease characterized by a block in differentiation of myeloid cells and their
uncontrolled proliferation in the bone marrow (1). The projected number of new diagnoses of AML in the United States in 2012 was nearly 14, 000, up from 12, 000 in 2010 (2).
The estimated number of deaths from these diagnoses was 10, 200, surpassing the number of deaths in 2010 by over 2000 (2). Until the 1970s, five-year survival rates for AML
were less than 15% (1). During the 1980s and 1990s refinements in the diagnosis and advances in therapeutic approaches improved the prognosis for patients with AML. Nonetheless, the survival rate among patients less than 65 years of age is still only 40% (1) and
the prospects for elderly AML patients is significantly worse, with median survival times
of only a few months (3). The dismal outlook for older patients is a result of not only
the deteriorating health of the patient but also the nature of the disease (4). When taken
with the fact that AML is the most common acute leukemia affecting adults (4), these
discouraging statistics highlight the importance of study of the disease. AML is diagnosed
by identification of leukemic myeloblasts in bone marrow exceeding 30% of marrow
aspirate (1). Recently, the relevance in classifying the subtype of AML and determining course of treatment based on the specific subtype has become appreciated (1, 5). The
most commonly used method of classification (known as the FAB classification system)
divides AML into nine distinct subtypes based on the particular myeloid lineage involved
and the degree of differentiation of the cells (1). These distinctions are determined by the
morphological appearance of the blasts and their reactivity with histochemical stains (1).
The FAB classification system was named after the group that developed it, the FrenchAmerican-British (FAB) group, and is listed in Table 1.1. The FAB classification system
also incorporates genetic trends, such as chromosomal rearrangements involving certain
genes that are present in a large percentage of AML patients (1). Specifically, genes that
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Table 1.1 FAB Classification of AML and associated genetic abnormalities/transcription factor mutations.
Table 1.1 adapted from Lowenberg et al. 1999 (1) and Rosenbauer & Tenen 2007 (6)

FAB
Subtype

Common Name
(% of Cases)

M0

Acute myeloblastic leukemia
with minimal differentiation
(3%)

Results of Staining
M
-

SB
-

NSE
-

Transcription Factor
(Frequency in AML)

Mutations and Effects

RUNX1 (9%)

Missense, nonsense or
frameshift mutations

EVI1 inv(3q26) and t(3;3)
PU.1 (<7%)

M1

Acute myeloblastic leukemia
without maturation (15–20%)

+

+

-

M2

Acute myeloblastic leukemia
with maturation (25–30%)

+

+

-

M3

Acute promyelocytic leukemia
(5–10%)

+

+

-

M4

Acute myelomonocytic leukemia +
(20%)

+

+

C/EBPα (7-9%)

Amino-terminal
dominant negative;
carboxy-terminal loss of
DNA binding
RUNX1-ETO t(8;21) (12-15%) RUNX1 DNA-binding
domain fused to the
transcriptional
corepressor ETO
DEK-CAN t(6;9)
C/EBPα (7-9%)
Amino-terminal
dominant negative;
carboxy-terminal loss of
DNA binding
PML-RARα t(15;17) (6-7%)
PML gene fused to
RARA
PLZF-RARα t(11;17)
NPM-RARα t(5;17)
MLL fusions t11q23 (4-7%)

DEK-CAN t(6;9)
EVI1 inv(3q26) and t(3;3)
PU.1 (<7%)
C/EBPα (7-9%)

M4EO

Acute myelomonocytic leukemia +
with abnormal eosinophils
(5–10%)

+

+

CBFβ-MYH11 inv16
(8-10%)

MLL gene fused with
one of 30 distinct genes
encoding partner
proteins

Amino-terminal
dominant negative;
carboxy-terminal loss of
DNA binding
Inversion of breaks in
chromosome 16; joins
CBFβ with the myosin
gene MYH11

CBFβ-MYH11 t(16;16)
M5

Acute monocytic leukemia
(2–9%)

-

-

+

M6
M7

Erythroleukemia (3–5%)
Acute megakaryocytic leukemia
(3–12%)

+
-

+
-

+

MLL fusions t11q23 (4-7%)
MOZ-CBP t(8;16)
PU.1 (<7%)
PU.1 (<7%)
t(1;22)

M7 with
GATA1 (Nearly 100% in
Amino-terminal
Down’s
AMKL associated with
dominant negative
syndrome
Down’s syndrome)
*AMKL, acute megakaryoblastic leukemia; CBFβ, core-binding factor- β; C/EBPα, CCAAT/enhancer binding protein-α; GATA1, GATAbinding protein 1; MLL, mixed lineage leukemia; MYH11, myosin heavy chain 11; PML, promyelocytic leukemia; RARα, retinoic acid
receptor-alpha; RUNX1, runt-related transcription factor 1
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encode DNA-binding transcription factors or the regulatory components of transcriptional
complexes are frequently subject to mutation (1). For example, the t(8;21) translocation
of the transcription factor acute myeloid leukemia 1 protein (AML1) (also known as runtrelated transcription factor 1, RUNX1 or core-binding factor subunit alpha-2, CBFα2),
which regulates a number of hematopoiesis specific genes (1), is found in 12-15% of
AML cases (6). The consequence of this chromosomal translocation is AML1 fusing to
the transcriptional corepressor ETO. The resultant chimeric protein, represses instead of
activating AML1-regulated target genes, including the genes encoding the transcription
factors Purine-Rich Box Binding (PU.1), CCAAT/enhancer binding protein alpha (C/
EBPα) and RUNX1 (6). Interestingly, mutation of AML1’s normal partner, core binding
factor-β (CBFβ) is associated with a different subtype of AML that involves chromosome
16 inversions (6-7). This transcription factor mutation is present in 8-10% of AML cases
(6). Examples of genetic mutations associated with the various FAB system subtypes of
AML are included in Table 1.1. Due to the fact that transcription factors are essential for
normal development of the hematopoietic system (6), it is not surprising that mutation
results in deregulation of hematopoiesis (1,6), and ultimately, in some cases, cancer. The
more recent World Health Organization (WHO) classification takes into account such
leukemia-associated molecular parameters (6).
Due to the important role that deregulated transcription factor activity can play in
leukemia, such genes are currently being targeted for therapeutic intervention in myeloid and other cancers (6). For example, in acute promyelocytic leukemia (APL; FAB
system subtype M3) a chromosomal translocation (t(15;17)) joins the gene encoding the
transcription factor promyelocytic leukemia (PML) to the gene encoding retinoic acid
receptor-α (RARα) (6, 8). It is well known that RARs play a role in the differentiation
of myeloid cells (9); Tsai and Collins have demonstrated that inhibition of RARα blocks
granulocytic differentiation (10). It has been shown that the PML- RARα fusion blocks
myeloid transcription factors, such as PU.1 and C/EBPα, resulting in a block in myeloid
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differentiation (6). The differentiation block can be relieved by treatment with all-trans
retinoic acid (ATRA), increasing the survival of patients with APL (6, 11). Given that the
hallmark of AML is a severe block in hematopoiesis, specifically myeloid differentiation
(6), understanding normal hematopoiesis and myeloid development is critical.

1.2 Hematopoiesis
Hematopoiesis is the development of all blood lineages from a hematopoietic
stem cell (HSC). HSCs exist as a small, rare population of cells in the bone marrow of
adult mammals (12). HSCs are derived from the mesodermal layer of the embryo, which
becomes specialized to a hematopoietic fate (12). Hematopoiesis, then, occurs in two
major waves, at four sequential locations, in mammals: 1) the yolk sac, 2) an area surrounding the dorsal aorta known as the aorta-gonad mesonephros (AGM) region, 3) the
fetal liver, 4) the bone marrow (13). The placenta has been acknowledged as an additional
site for hematopoiesis, during the AGM to fetal liver period (13). In the mouse, the first
or “primitive” wave of blood production in the mammalian yolk sac yields red blood cells
(erythroid cells) that enable tissue oxygenation as the embryo grows (13). The primitive
wave begins at embryonic day 7.5 in the blood islands of the yolk sac and shortly after (~
embryonic day 8.5) in the AGM region. The AGM region produces hematopoietic progenitor cells. The primitive hematopoietic system is rapidly replaced by adult-type hematopoiesis, known as “definitive” hematopoiesis, that begins at ~ embryonic day 10 (13).
This second wave, in the mouse, involves the fetal liver, thymus, spleen, and ultimately
the bone marrow; the second wave generates blood cells of specific lineages, such as B
cells and T cells (13). Definitive hematopoiesis occurs first in the fetal liver, with maximal hematopoietic activity occurring embryonic day 14.5. Following embryonic day 15,
hematopoiesis decreases in the fetal liver, presumably as hematopoiesis begins to occur
in other immune organs such as the bone marrow and spleen (14). By embryonic day 20,
hematopoiesis is underway in the bone marrow where it will occur for the remainder of
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the animal’s life (14). As indicated, the developmental time periods for hematopoiesis
mentioned, are for that of mice. Notably, there are differences between humans and mice,
but the mouse model provides foundational information for understanding the development of the hematopoietic system (15).
The hematopoietic stem cell has two defining characteristics: self-renewal and
multipotency (16). Self-renewal is the ability to undergo many cellular divisions while
remaining undifferentiated. This includes the option of dividing asymmetrically, which
allows one daughter cell to maintain the HSC population while allowing the second
daughter cell to differentiate. Multipotency is the ability to differentiate into cell types of
multiple different lineages. The HSC has the ability to generate progenitors, which differentiate into all lineages of the blood in a hierarchal fashion (17). Multipotent stem cells
go on to divide to produce a common lymphoid progenitor which gives rise to the lymphoid lineage, or a common myeloid progenitor which gives rise to the myeloid lineage.
Terminally differentiated cell types of the lymphoid lineage include natural killer (NK)
cells and the T and B lymphocytes, while terminally differentiated cells of the myeloid
lineage include macrophages, dendritic cells, neutrophils, eosinophils, basophils, mast
cells, erythrocytes (red blood cells) and megakaryocytes that generate platelets (18).
More specifically, then, hematopoiesis is the acquirement of defining blood cell phenotypes as a result of coordinated, cell-specific gene expression (19). Molecular pathways,
including cytokine receptors and cell specific transcription factors, have been identified
as regulators controlling the different blood cell lineages (19-21). Zhu and Emerson have
proposed that it is the effects of both intrinsic transcription factors and external signaling
pathways initiated by cytokines that govern stem cell fate decisions (21).
Multicolour flow cytometry has permitted the identification of phenotypically
distinct stem-cell and intermediate-precursor populations (6). The Weissman laboratory
has proposed an ordered sequence of hematopoiesis, beginning with a subpopulation of
long-term HSCs (defined phenotypically as LIN-IL-7Rα-SCA1+KIT+FLT3-Thy1lowCD34-)
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(6). The LIN marker represents a group of antigens on mature hematopoietic cells; the
LIN panel includes CD11b, Gr-1, B220, TER119, CD4, CD8, CD5, and CD3. These
cells have the ability for life-long self-renewal and multilineage differentiation (6).
Long-term HSCs give rise to short-term HSCs (defined phenotypically as LIN-IL-7RαSCA1+KIT+FLT3lowThy1lowCD34+), which retain the ability for multilineage differentiation potential, but have less self-renewal potential (6). The short-term HSCs give
rise to the multipotential progenitors (MPPs) (defined phenotypically as LIN-IL-7RαSCA1+KIT+FLT3lowThy1-CD34+), which have lost self-renewal potential but are still
able to differentiate into all blood-cell types (6). From this point, the MPPs give rise
to either the common lymphoid progenitor (CLP) (defined phenotypically as LIN-IL7Rα+SCA1lowKITlow) or the common myeloid progenitor (CMP) (defined phenotypically
as LIN-SCA1-KIT+CD34+FcγRII-FcγRIII-) (23, 24). The Weissman model proposes that
all myeloid cells arise from CMPs. The CMP goes on to give rise to more specified progenitors including granulocyte/monocyte progenitors (GMPs) (defined phenotypically as
LIN-SCA1-KIT+CD34+FcγRII+FcγRIII+), megakaryocyte/erythroid progenitors (MEPs)
(defined phenotypically as LIN-SCA1-KIT+CD34-FcγRII-FcγRIII-), and as has recently
been shown, basophil progenitors (25), as well as a shared macrophage and dendritic cell
progenitor (MDP) (26). From these various progenitors, the terminally differentiated cell
types are established. The hematopoietic lineage diversification system proposed by the
Weissman group is summarized in Figure 1.1A.
The Weissman model has recently been challenged by Jacobsen and colleagues,
who propose that the erythroid lineage diverts much earlier, without going through a
shared CMP stage (27). The Jacobsen model states that following differentiation from
a long-term HSC into a short-term HSC the short-term HSC differentiates into either a
MEP, or a lymphoid-primed multipotent progenitor (LMPP). The LMPP then differentiates into the GMP, leading to granulocytes and macrophages, or the CLP, leading to
NK cells, B cells and T cells (27). The Jacobsen model is illustrated in Figure 1.1B. The
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Figure 1.1 Current Models of Hematopoiesis.
Figure 1.1 adapted from Rosenbauer & Tenen 2007 (6) and Reya et al. 2001 (22)
(A) Classical/Weissman model of hematopoiesis. CLPs are thought to generate T and
B-cells, while CMPs give rise to GMPs, MEPs, MDPs, and mast-cell and basophil progenitors. (B) Jacobsen model of hematopoiesis. The Jacobsen model states that MEPs
are the direct progeny of ST-HSCs, while all myeloid and lymphoid lineages are the
progeny of LMPPs.
Long-term (LT) and short-term (ST) hematopoietic stem cell (HSC); Multipotent progenitor (MPP); Common lymphoid progenitor (CLP); Common myeloid progenitor (CMP);
Granulocyte/macrophage progenitor (GMP); Megakaryocyte/erythroid progenitor (MEP);
Macrophage/dendritic cell progenitor (MDP); Lymphoid-primed multipotent progenitor
(LMPP).
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Jacobsen model is most compatible with the finding that PU.1 deficient mice are devoid
of CLPs and CMPs, but have relatively normal numbers of erythroid cells (6). Furthermore, several other alternative models of hematopoiesis have been proposed including
but not limited to the stochastic model, the sequential restriction model, myeloid-based
models, as well as models based on studies of transcription factors (28). In conclusion,
while much progress has been made in understanding hematopoiesis, more research is
still required to establish a complete pathway to the development of blood cells.

1.3 Transcriptional regulation of myeloid cell development
Myelopoiesis is the developmental process of producing differentiated cells of
the myeloid lineage from HSCs. Transcription factors play a pivotal role in myeloid cell
differentiation (29-35). The myeloid lineage comprises most of the cells of the innate immune system and includes monocytes/macrophages, neutrophils, eosinophils, basophils,
mast cells and dendritic cells (18). Erythrocytes (red blood cells) and megakaryocytes
have also been traditionally considered part of the myeloid lineage, though that view has
recently been challenged with the Jacobsen model (27). Myeloid cells, specifically granulocytes (collective term for neutrophils, eosinophils, and basophils) (18) and monocytes,
are key mediators of the inflammatory response (32). Myeloid cells mediate recognition,
ingestion, and destruction of foreign organisms, antigen presentation, cytokine production, and other functions of the immune and inflammatory reactions (32). HSCs in fetal
liver or in adult bone marrow give rise to GMPs, which in turn give rise to granulocyte,
monocyte, and granulocyte/monocyte-colony forming units (CFU-G, CFU-M, CFU-GM)
(33). Of note, GMPs share with CLPs the ability to generate myeloid dendritic cells (33).
Cell development and differentiation is defined by gene expression patterns
(33). Accordingly, transcription factors play a pivotal role by inducing the expression
of lineage-specific markers (33). While there is no single regulator of myelopoiesis, the
formation of cells of the myeloid lineage is controlled by a relatively small number of

10
transcription factors that regulate expression of myeloid specific genes, such as those
encoding receptors for macrophage colony-stimulating factor (M-CSF) and granulocyte
macrophage colony-stimulating factor (GM-CSF)(6, 16, 30-32). Table 1.2 illustrates transcriptional regulators of granulocytic and monocytic genes. Notably, numerous reports
have identified two key, non-redundant, transcription factors as absolutely critical for
normal myeloid cell development: PU.1 and C/EBPα (30-32). Knock-out studies of these
factors reveal major distortion of myeloid development (36-41). Furthermore, aberrant
expression of these two transcription factors has been shown to contribute to the pathogenesis of AML (6, 32, 42-47). As mentioned, in addition to transcriptional regulation,
cytokine activity has also been shown to influence hematopoiesis (32). While signaling
through cytokine receptors modulates factor activity, whether or not they can actually
determine cell fate has been contested (32, 33).
Although myelopoiesis cannot occur in the absence of either C/EBPα or PU.1,
normal myeloid cell development also requires the cooperation of several other transcription factors. The very first transcription factors to play a role, are those that orchestrate
the formation of HSCs from earlier stem cells of the mesoderm: RUNX1 (AML1) and
stem-cell leukemia factor, SCL (also known as T-cell acute lymphocytic leukemia protein, TAL1, encoded by the gene TAL1) (6). Confirmation of the importance of these two
transcription factors, come from studies that illustrate that both RUNX1-/- and TAL1-/- mice
are embryonic lethal and have no detectable hematopoiesis, (48, 49).
C/EBPα is necessary for production of GMPs from CMPs (6). Interestingly, C/
EBPα is expressed by HSCs, myeloid progenitors (CMPs, GMPs), and granulocytes, but
not by macrophages (24, 50). Several CEBPA gene knockout studies have demonstrated
that lack of C/EBPα results in a block of the CMP to GMP transition (31). CEBPA-/- mice
lack GMPs and granulocytes (neutrophils and eosinophils) but retain monocytes (36, 37).
It is also necessary to highlight the early differentiation block of granulocytes in CEBPA-/mice; C/EBPα is no longer required for granulocytic differentiation beyond the GMP
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Table 1.2 Regulation of Granulocytic and Monocytic Genes.
Table 1.2 adapted from Friedman 2002 (26)

Protein
Early-stage granulocytes
mim-1
Myeloperoxidase (MPO)
Neutrophil elastase (NE)
Myeloblastin (MBN)
G-CSF receptor
GM-CSF receptor
CD13
Lysozyme
c-fes
Early-stage monocytes
M-CSF receptor
Lysozyme
Late-stage granulocytes
gp91phox
Lactoferrin (LF)
FcγRI
Late-stage monocytes
Macrosialin
Scavenger receptor (type I)
Scavenger receptor (type II)
CD14
gp91phox
CD11b
CD18
FcγRI
FcγRIIIA

Transcriptional Regulators of gene
encoding protein
C/EBPs, c-Myb
C/EBPs, PU.1, CBF, c-Myb
C/EBPs, PU.1, CBF, c-Myb, Sp1
C/EBPs, PU.1, c-Myb
C/EBPs, PU.1
C/EBPs, PU.1
c-Myb, Ets-1 or Ets-2, c-Maf
C/EBPs, PU.1
PU.1, Sp1
C/EBPs, PU.1, CBF, c-Jun
C/EBPs, PU.1

PU.1, IRF‐8, CDP
C/EBPs, Sp1, CDP
PU.1
PU.1, c‐Jun
PU.1, c‐Jun
PU.1, c‐Jun
C/EBPs, Sp1
PU.1, IRF‐8, CDP, Hox10A
PU.1, Sp1
PU.1, Sp1
PU.1
PU.1
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stage, as conditional deletion of CEBPA in GMPs allows for normal granulopoiesis (37).
In addition to its role in myeloid differentiation, and regulation of myeloid specific genes
(see Table 1.2), C/EBPα also controls stem-���������������������������������������������
cell self-renewal properties (37) and coordinates cell-cycle exit (51).
The transcription factor c-Myb has also been implicated as a requirement for early
granulopoiesis (33). Like MYC, MYB is a proto-oncogene that promotes proliferation and
thus must be down-regulated for terminal myeloid differentiation to occur (34). Consistent with c-Myb’s role in the early stages of differentiation is the fact that c-Myb activates
early granulocyte genes including the genes encoding CD13, neutrophil elastase, myeloperoxidase, and myeloblastin (34) (Table 1.2). C-Myb is expressed in immature myeloid,
lymphoid, and erythroid cells, and MYB-/- mice lack each of these lineages (30, 33).
RARα is also connected with early granulocytic differentiation. While RARs are
widely expressed, RARα is preferentially found in myeloid cells (52). Dominant inhibition of RARα arrests granulocytic differentiation at the promyelocytic stage (10). Importantly, RARα activates the CCAAT/enhancer binding protein epsilon (C/EBPε) gene
promoter linking RARα to granulocyte development (53).
From the GMP stage, the next major milestone is designation of granulocytic
versus monocytic/macrophage fate. PU.1 binding partners have been shown to play a role
in terminal monopoiesis. PU.1 interaction with the interferon-���������������������������
γ��������������������������
(IFN- γ)-responsive transcription factor IRF8 (interferon regulatory factor 8) (also known as interferon consensus
sequence binding protein, ICSBP) has been implicated in monopoiesis (31). In the myeloid lineage, IRF8 is expressed by progenitors and macrophages, but not by granulocytes
(54). IRF8-/- mice have reduced macrophages and increased granulocytes (55).
Other transcription factors, including c-Jun and c-Fos, also cooperate with PU.1
to regulate myeloid genes and monocytic differentiation (56-58). C-Jun assists PU.1 by
either binding to adjacent DNA elements or by direct physical interactions. Physical interaction occurs between PU.1 and c-Jun via their DNA binding domains; this interaction
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permits the pair to activate gene transcription (59). Jun proteins (c-Jun, JunB, JunD) are
part of the bZIP, AP-1 subfamily of transcription factors that heterodimerize with c-Fos,
Fos B, Fra1 or Fra2 (31). Intriguingly, c-Jun and c-Fos can also heterodimerize with C/
EBPα to induce monocyte commitment (60).

Furthermore, the Maf transcription factor family (MafB, c-Maf) can zipper with

Fos or Jun family members (30). MafB is expressed in monocyte/macrophage cells and
exogenous MafB or c-Maf leads to monocytic differentiation (31). A role for MafB in late
but not early monocyte lineage development has been suggested (31).
In regards to late granulocytic specification, transcription factors involved include
C/EBPε, and growth-factor independence-1 (GFI1). While C/EBPα����������������
is the predomi-

nant isoform in immature granulocytes, C/EBPε predominates mature granulocytes (32).
A clear role for C/EBPε in the regulation of terminal granulopoiesis is evident from the

phenotype of C/EBPε deficient mice, which have immature granulocytes (neutrophils and
eosinophils) that fail to develop normally past the promyelocyte stage and lack secondary
granules (61-63). As well, the presence of C/EBPε regulatory sites in the promoters of

genes expressed in neutrophils is highly suggestive of C/EBPε��������������������������
as a key player in granulocytic differentiation (30). Similarly, GFI1-/- mice lack neutrophilic granulocytes (6).

Notably, the development of early myeloid progenitors, including GMPs, was normal in
GFI1-/- mice, but neutrophilic differentiation was blocked beyond the promyelocyte stage
(64). This finding confirms the role of C/EBPα in early granulocyte development, and

illustrates the significance of other factors, such as GFI1, in later stages of granulopoiesis.
Finally, GFI1-/- mice accumulated neutrophil precursors that expressed monocyte-specific genes in addition to early granulocyte markers. The abnormal neutrophil population
present in GFI1-/- mice correlates with the fact that GFI1 contains a transcriptional repressor and may function to repress monocyte/macrophage lineage traits during granulocytic
maturation (64).
The transcription factor Specificity Protein 1 (Sp1), has also been implicated in
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terminal granulopoiesis (as well as monopoiesis). This implication is based on the fact
that Sp1 regulates several granulocytic and monocytic genes, including the genes encoding lactoferrin (LF) (granulocytic), CD14 and CD11b (monocytic) (see Table 1.2) (30).
Furthermore, Sp1 is expressed at particularly high levels in maturing granulocytes (30).
Like GFI1, recent studies have shown that the transcription factors early growth
response proteins 1 and 2 (EGR1, EGR2), NGF1-A-binding protein 2 (NAB2), CCAAT
displacement protein (CDP), and Homeobox protein Hox-A10 (HoxA10) repress terminal
differentiation (31). Laslo et al. have identified the EGR proteins and NAB2 as possible
repressors of granulopoiesis, while stimulating monopoiesis (65). Evidence for the notion that EGR:NAB2 complexes repress granulopoiesis stems from the fact that EGR2 or
NAB2 knockdown induces neutrophilic genes, including GFI1, and EGR2:NAB2 represses the GFI1 promoter (65). GFI1 represses the EGR2 promoter (65), providing further
support for GFI1 as a transcriptional repressor of monopoiesis. In maturing neutrophils,
the gp91phox promoter region, (gp91phox is a late stage granulocyte and monocyte gene)
is repressed by both CDP and HoxA10 (66-67). CDP represses transcription by competing with transactivators for the same site (DNA elements that resemble the 5’-CCAAT-3’
motif) (68). Work by Skalnik et al., as well as Eklund et al., suggest that levels of CDP
and HoxA10 decrease during terminal neutrophil and monocyte differentiation (66-67).
Due to the fact that HoxA10 is preferentially expressed in immature myeloid cells (33), it
has been postulated that HoxA10 plays a role in maintaining an earlier stage in myelopoiesis and inhibiting terminal differentiation (33). In conclusion, myeloid cell development
is achieved via cooperative gene regulation, protein-protein interaction, autoregulation,
regulation of factor levels, and induction of cell cycle arrest (33).

1.4 Purine-Rich Box Binding-1 (PU.1)
PU.1 is a member of the family of E26 transformation specific (ETS) transcription
factors. Members of this family of proteins all contain a characteristic winged-helix-turn-
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helix DNA binding domain that binds DNA sequences with a GGA core (“GGAA”) (6970). PU.1 binds as a monomer to the purine-rich consensus DNA sequence (from which it
derived its name) 5’GAGGAA-3’ (PU box) via its C-terminal ETS DNA binding domain
(71).
In 1988, PU.1 was first discovered as a putative oncogene isolated from a murine
Friend virus-induced erythroleukemia (72). The murine erythroleukemia was induced by
a proviral insertion of the retroviral spleen focus forming virus (SFFV) (72). The gene
encoding PU.1 became known as SPI1 (SFFV proviral integration site-1), in humans, and
Sfpi1, in mice (72). Interestingly, Paul et al. found that overexpression of PU.1 blocks
erythroid differentiation (73). The murine PU.1 protein contains 266 or 272 amino acids
due to two potential translation start codons, and is ~42 kilodaltons (kDa) in size (74).
The human PU.1 protein is quite similar, demonstrating 85% homology with murine
PU.1 (75). As indicated, PU.1 expression is restricted to blood cells (71), where it plays a
fundamental role in the development of both myeloid and lymphoid lineages (41).
In addition to DNA binding, the C-terminal ETS DNA binding domain of PU.1
can also interact with other proteins, including C/EBPα, CCAAT/enhancer binding protein beta (C/EBPβ), c-Jun and GATA-binding factor 1 (GATA-1) (59, 76-78) (Figure 1.2).
PU.1 contains two other functional domains: an N-terminal transactivation domain, incorporating an acidic and a glutamine rich region, and a PEST domain (79). While PU.1 activates transcription via its N-terminal domain (79), this region also allows for interaction
with other proteins such as GATA-1, TATA box binding protein (TBP) and Retinoblastoma protein (pRb) (78, 74) (Figure 1.2). TBP is a subunit of the basal transcriptional complex TFIID, which increases RNA polymerase II activity, and pRb is a regulator of cell
cycle progression (74). The PEST domain is located between the transactivation domain
and the ETS domain; PEST was named after its high content of proline (P), glutamic acid
(E), serine (S), and threonine (T). This domain is involved in protein stability/degradation (74, 80). Furthermore, phosphorylation of PU.1 within its PEST domain, allows it to
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Figure 1.2 Protein-protein interactions involving PU.1. The transcription factor PU.1
is illustrated, with its three domains: N-terminal transactivation domain (blue), PEST domain (red), and C-terminal ETS DNA binding domain (green). The proteins that interact
with each domain within PU.1 are also labeled within the corresponding domain.
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interact with IRF4 and IRF8 (31) (Figure 1.2).

1.5 The expression and regulation of PU.1 in myeloid development
PU.1 is widely expressed among the various blood lineages. PU.1 is expressed in
HSCs, CMPs, CLPs, GMPs, monocytes, granulocytes, and B cells (6). Recent analysis
has shown that the absence of PU.1 impairs the ability of HSCs to self-renew and prevents differentiation into CMPs and CLPs (38, 81). Importantly, PU.1 expression levels
appear to be a crucial determinant in cell-fate decisions of both myeloid and lymphoid
progenitors. PU.1 is expressed at similar levels in HSCs, CMPs, CLPs, and B cells, but
its expression increases substantially during terminal myeloid (granulocytic and monocytic) differentiation (47, 82-83). Furthermore, Singh’s group illustrated how high levels
of PU.1 induce commitment to the myeloid lineage, while lower levels induce B cell development (84). By contrast, PU.1 expression is downregulated early on during erythroid
and T cell differentiation (72, 85-86). Recent evidence, however, has shown that certain
subsets of T cells must re-express PU.1 during terminal differentiation. This includes a
subset of IL-9 producing helper T cells (87). In cell lines, PU.1 is expressed by myeloid
and B cells, but not by T cell lines (71, 88). When examining the myeloid lineage, specifically, it has been observed that high PU.1 levels support the production of macrophages,
whereas low PU.1 levels support granulocyte production (47, 89-90). For example, one
study found that expression of low levels of PU.1 in Sfpi1-/- cells induces granulopoiesis,
while high levels induce monopoiesis (89). As well, expression of PU.1 at 20% of wildtype levels resulted in a loss of monopoiesis, but maintenance of granulopoiesis (47). In
short, it is clear PU.1 expression is absolutely critical throughout myeloid cell development, beginning from the HSC stage (6).
Due to the significance of PU.1 levels in hematopoietic lineage commitment,
regulation of PU.1 expression is essential. Many groups have shown that inappropriate
expression of PU.1 will lead to anomalous development of the hematopoietic system and
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may result in leukemia (91). Several different transcription factors regulate PU.1 expression, including Octamer (Oct-1 and 2), Sp1, GATA-1, C/EBPα, RUNX1, and PU.1 itself.
Chen et al. have reported an octamer binding site 55 bp upstream of the transcriptional
start site (TSS) (92). While both Oct-1 and 2 can bind specifically to the site -55 bp of the
Sfpi1 promoter, Oct-2 expression is limited to B cells, while Oct-1 is expressed ubiquitously (92). Interestingly, a recently identified octamer coactivator, known as Bob1 (93),
OBF-1 (94), or OCA-B (95), is expressed exclusively in B cells (92). This may explain
why the octamer site is relatively more important for PU.1 expression in B cells than
myeloid cells, where PU.1 itself is most important (92). The same group detected both a
Sp1 and PU.1 binding site within the Sfpi1 promoter at -40 bp and +20 bp, respectively
(92, 96). In myeloid cells, the PU.1 binding site (+20 bp) is located in the 5’-untranslated
region of the Sfpi1 promoter and has been shown to be functionally important, leading to
an autoregulatory loop (96). In addition, Okuno et al. recently proposed a second potential autoregulatory mechanism involving an upstream regulatory element (URE). Okuno
et al. demonstrate that PU.1 binds a distal site located 14 kb upstream of the TSS (in
mice) and mutation of this site, abolishing PU.1 binding, results in a decrease in PU.1 expression (97). Intriguingly, deletion of the URE in mice reduces PU.1 expression to 20%
of wild-type levels in HSCs, myeloid cells, and B cells (47). The same distal element is
located 17 kb upstream of the TSS in humans (6). Thus, PU.1 may be able to positively
regulate its own expression through both the URE and the PU.1 promoter. RUNX1 also
binds to the same distal enhancer as PU.1 itself, thereby controlling PU.1 expression (98).
RUNX1 binds to three sites within the URE of PU.1 and regulates PU.1 both positively
and negatively in a lineage dependent manner (98). The mutual antagonism between
PU.1 and GATA-1 is another well-known example of PU.1 gene regulation. A GATA1 binding site 15 bp upstream of the TSS has been observed (52, 92, 96). Furthermore,
Zhang et al. demonstrate that interaction between PU.1’s ETS domain and the C-terminal
zinc finger of GATA-1 inhibits PU.1 activation of myeloid target genes (99). They also
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show that GATA proteins inhibit binding of PU.1 to c-Jun, a coactivator of PU.1 transactivation (99). The ability of GATA-1 to repress myeloid gene expression via interaction
with the PU.1 ETS DNA binding domain and subsequent interference of PU.1 function
has been confirmed by Nerlov et al. (100). Similarly, C/EBPα blocks the function of PU.1
through protein-protein interaction (73). As well, the leucine zipper in the DNA binding
domain of C/EBPα interacts with the β3/ β4 region in the ETS domain of PU.1, resulting
in displacement of c-Jun. (78). Finally, PU.1 expression is also upregulated by the Notch1
signaling pathway (101).

1.6 The role of PU. 1 during myeloid development
Knock-out, knock-in, overexpression, reduction, and restoration studies clearly
indicate the problems that arise in the absence of normal PU.1 levels. Two labs, in particular have played pivotal roles in our understanding of PU.1 by creating an Sfpi1-/- mouse
model. The first lab, of Dr. Harinder Singh, replaced PU.1’s ETS DNA binding domain
with the neomycin resistance gene. In their model, Sfpi1 deletion was embryonically
lethal between days 16.5 and 18.5 of gestation. Upon analysis of PU.1 (-/-) fetal liver, no
myelocytes (or lymphocytes) were detected (40), indicating an early and severe differentiation block on myelopoiesis. The second group, Dr. Richard Maki’s, created their Sfpi1-/mouse by inserting the neomycin-resistance gene into the ETS domain. Dr. Maki’s group
was able to generate pups, though they died of septicemia within 2 days, and again no
mature granulocytes or macrophages were detected (41). Interestingly, Sfpi1-/- pups were
able to survive up to 2 weeks with antibiotics and these older mice contained a small population of abnormal neutrophils and macrophages (41). Thus, both models demonstrate
obvious defects in myeloid cell development. While a complete absence of PU.1 expression has severe effects, other groups have looked at a reduction in PU.1 expression and
found similar problems. Dr. Daniel Tenen’s group was the first to report that AML could
be induced by a decrease in PU.1 expression (47). Tenen’s group generated a hypo-
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morphic Sfpi1 allele, by replacing the -14 kb URE with a neomycin resistance gene. Mice
homozygous for this ΔUREneo allele expressed PU.1 at 20% of normal levels (47). These
mice had an accumulation of abnormal, immature myeloid precursors in the bone marrow
and spleens, that were responsive to G-CSF, but not M- or GM-CSF (47). Furthermore,
myeloid differentiation was blocked in mice homozygous for the Sfpi1 allele that reduces
PU.1 expression, and these mice eventually developed AML (43).
Our laboratory has generated a novel hypomorphic allele of Sfpi1 termed BN, which
also produces PU.1 at 20% of wild-type levels (102). The allele was generated by mutation of the first coding exon (102). Within this region, two ATG translation start sites were
replaced with a β-lactamase gene/neomycin resistance cassette (102). A third translational
start codon exists within Sfpi1 enabling Sfpi1BN alleles to be transcribed, but resulting in a
slightly truncated protein. Due to altered transcriptional regulation, it also results in PU.1
being expressed at a reduced level. Nonetheless, the protein itself is fully functional (102).
Neonatal mice homozygous for the mutated Sfpi1 allele (Sfpi1BN/BN mice) are characterized by a hyperproliferation of immature myeloid cells in their bone marrow and spleen,
as well as a complete absence of B-cells (98). Sfpi1BN/BN mice survive only 1-3 weeks following birth and demonstrate severe phenotype abnormalities, including osteopetrosis and
reduced physical size (102).

1.7 Transcriptional targets of PU.1
The importance of PU.1 in myeloid cell development is highlighted by the presence of PU.1 binding motifs in the regulatory sequences of almost all myeloid-specific
genes, as illustrated in Table 1.2 (6, 32). Notable PU.1 target genes include the genes encoding the receptors for essential cytokines as M-CSF, GM-CSF, and granulocyte colonystimulating factor (G-CSF) (103-106). The growth factors that the M-CSFR, GM-CSFR,
and G-CSFR bind are required for the proliferation and differentiation of myeloid cells.
PU.1 also activates genes necessary for the myeloid phenotype, including the genes en-
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coding CD11b, CD18, FcγRI/IIIA, and scavenger receptors, type I and II (107-111) (see
Table 1.2). CD11b is a cell surface marker expressed on mature monocytes, macrophages,
and granulocytes (107); the β2 leukocyte integrin CD18, together with CD11b forms
the complex macrophage-1 antigen, Mac-1 (complement receptor 3, CR3), which plays
several important roles in immune and inflammatory responses (108). The high-affinity
Fc gamma receptor I (FcγRI) and the low-affinity Fc gamma receptor IIIA (FcγRIIIA)
are both expressed exclusively in the myeloid lineage and are receptors for the Fc domain
of immunoglobulin G (IgG). They play an important role in innate immunity through
their ability to induce phagocytosis and trigger antibody-dependent cellular cytotoxicity
(109-110). Expression of type I and II scavenger receptors (SRs) is highly restricted to
monocytes/macrophages; SRs are maximally expressed during monocyte to macrophage
differentiation (111). Finally, recent studies by Ghisletti et al. demonstrate that PU.1 helps
control expression of inflammatory genes, such as the genes encoding interleukin-1 beta
(IL-1 β), interleukin-18 (IL-18), interleukin-12 subunit p40 (IL12p40 subunit), and tumor
necrosis factor (TNF), in macrophages (112).

1.8 The Cell Cycle
Cell cycle exit is necessary for terminal differentiation to occur (33). Without cell
cycle arrest, immature cells will continue to proliferate, possibly leading to the development of cancer. One of the hallmarks of cancer is cell cycle deregulation (113-114). Cell
cycle deregulation can occur at different levels of the cell cycle control network (115).
The cell cycle is a process by which DNA is replicated and then separated into
two new cells (115). The process is divided into four distinct stages: G1, S, G2 (collectively known as interphase) (116), and mitosis (M) (115). DNA replication occurs during
S phase and is preceded by G1 phase, in which the cells are preparing for DNA synthesis.
Following synthesis, the cells enter a second gap phase (G2), in which the cell prepares
for mitosis. The actual segregation of chromosomes into two separate cells occurs during

Figure 1.3 Control of the cell cycle. The stages of the cell cycle and sites of activity
of regulatory CDK/cyclin complexes are presented. Cyclin dependent kinase inhibitors
(CKIs), p15 and p27 are also indicated. As well, the G1 to S phase transition involving
pRb and E2F1 is illustrated.
P (phosphorylation); * demonstrates the CDK7-cyclin H complex throughout all phases
of the cell cycle; → (activation);

(repression)

23

24

Cyclin H
CDK7

*

=

Cyclin A
CDK2

Cyclin E
CDK2

*

P

P

Cyclin A

*

CDK1

P

E2F1

HDAC
E2F1

P

pRb
HDAC

*

pRb

p15

Cyclin D
CDK4/6

p27
CDK4/6

P

Cyclin B
CDK1

*

p27

P

25
mitosis, which is divided into prophase, metaphase, anaphase, telophase (115). A resting
state, known as G0, also exists within the cell cycle. G0 is a departure from the G1 stage
and cells can enter G0 before making the commitment to S phase. Cells in the G0 stage
are non-growing and non-proliferating (115) (Figure 1.3).
Transition through the various phases of the cell cycle is highly regulated; it is
controlled by numerous mechanisms including cyclin-dependent kinases (CDKs), cyclins, CDK inhibitors (CKIs), phosphorylating events, and CDK activating enzymes.
CDKs are key regulators of the cell cycle. They are a family of serine/threonine protein
kinases that are activated at specific points of the cell cycle (115). Once activated CDKs
phosphorylate other proteins to induce downstream processes necessary for cell cycle
progression (116-117). Five of the nine CDK family members are active during the cell
cycle at various points. Figure 1.3 illustrates the five CDK family members (CDK4,
CDK6, CDK2, CDK1, CDK7) that are active during the cell cycle and the particular
stage at which their presence is required. CDK7 acts in combination with cyclin H as
CDK activating kinases (CAK) (118); the CAK complex is required throughout all cell
cycle phases (115). Furthermore, CDKs require activation from another group of regulatory proteins, known as cyclins, that complex with CDKs in order to regulate the cell
cycle. While CDK protein levels remain stable during the cell cycle, cyclin levels fluctuate; when the level of a cyclin protein rises it is able to activate its particular CDK (115).
As illustrated, different cyclins act at different stages of the cell cycle to activate different
CDKs. D cyclins (D1, 2, and 3) bind to CDK4 and CDK6 to permit entry into G1 phase.
Cyclin E associates with CDK2 to regulate progression from G1 to S phase. A CDK2cyclin A is required during S phase. In late G2 and early M, a CDK1-cyclin A complex
is formed to promote entry into M. The remainder of M is regulated by a CDK1-cyclin
B complex (115) (Figure 1.3). In addition to cyclins, CDK activity is further regulated
by phosphorylation. Some CDKs, such as CDK1, require phosphorylation to become
fully active 115) (Figure 1.3). Phosphorylation induces conformational changes that en-

26
able CDKs to better bind cyclins (119). While CDK activating kinases, such as the CAK
complex act on CDKs, so do CDK inactivating kinases. Similarly, cell cycle inhibitory
proteins, known as CDK inhibitors (CKI) also regulate CDK activity (115). There are two
relevant families of CKIs: the INK4 family, which includes p15 (INK4b), p16 (INK4a),
p18 (INK4c) and p19 (INK4d), and the Cip/Kip family, which includes p21 (Waf1, Cip1),
p27 (Cip2), and p57 (Kip2) (115). The INK4 family inactivates G1 CDKs (CDK 4 and 6)
by preventing cyclin binding (120) (Figure. 1.3). The Cip/Kip family inactivate CDKcyclin complexes (121), specifically the G1 CDK-cyclin complexes, and to a lesser extent
the CDK1-cyclin B complex (122) (Figure 1.3).
As mentioned, once active, CDKs are able to phosphorylate target proteins, which
ultimately leads to cell cycle progression. The pathway controlling the progression of
cells from G1 into S phase is well established (123-124) and involves the CDK4/6-cyclin
D complex and its substrate, the product of the retinoblastoma tumour suppressor gene,
pRb (115). In this scenario, CDK4/6 phosphorylates pRb in early G1 phase, resulting in
disruption of the pRb-HDAC (histone deacetylase) complex and release of the transcription factors E2F1 and DP1 (115) (Figure 1.3).
E2F1 and DP1 are members of two different groups of proteins that heterodimerize to induce transcription (123, 125). The two different groups are the E2F gene family consisting of six E2F genes (E2F1-E2F6), and the DRTF (differentiation regulated
transcription factor) protein (DP) gene family, which consists of two DP genes (DP1 and
DP2) (123). Thus, heterodimers contain a subunit encoded by the E2F gene family and a
subunit encoded by the DP gene family (123). E2F1-DP1 heterodimers positively regulate transcription of genes whose products are required for S phase progression, including
cyclin A and cyclin E (115).

1.9 E2F1, PU.1 and AML
It is now well-established that the transcription factor E2F1 can promote entry
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into S phase from G1 (126-127). As indicated above, E2F1 (when complexed with a
DP) controls the transcription of genes essential for cell division; these include genes
encoding cell cycle regulators (such as the cyclins indicated above), enzymes involved
in nucleotide biosynthesis (such as thymidine kinase), and the main components of the
DNA-replication machinery (126). The potency of E2F1 as a transcriptional activator
has been shown through overexpression of the protein, which induces quiescent cells to
re-enter the cell cycle (127-129). Furthermore, deregulation of E2F1 activity appears to
be a characteristic of human cancers (125, 130). E2F1 is regulated via association with
pRb; once pRb is phosphorylated by CDK-cyclin complexes, E2F1 is released. Thus,
pRb restricts cell cycle progression by maintaining E2F1 and the disassociation of E2F1
from pRb drives proliferation (123). The idea that defects in regulation and inappropriate release of E2F1 might induce cancer, are illustrated by the fact that overexpression
of E2F1 can induce transformation of primary cells (131-133). Moreover, Gibbs et al.
have shown that deregulated expression of E2F1 blocks terminal myeloid differentiation,
resulting in proliferation of immature myeloid cells (134). In addition to inducing proliferation, deregulated E2F1 activity can also trigger apoptosis (122, 126). This functional
paradox of E2F1 has been investigated and the results demonstrate that E2F1 can have
both oncogenic (through its role in cell cycle progression) and tumor-suppressive effects
(through apoptosis induction) (130).
Certain hematopoietic transcription factors, such as, c-Myb, and c-Myc, promote
proliferation, and are down-regulated upon differentiation (34), while others, such as C/
EBPα promote cell-cycle arrest (6). Several different mechanisms by which C/EBPα acts
on the cell cycle have been reported. The most important mechanism, however, appears
to be repression of E2F1 activity. This is suggested by the fact that targeted mutation in
the gene encoding C/EBPα that results in defective repression of E2F1 failed to support
granulocytic differentiation (6). On the other hand, mice lacking the CDK2/CDK4binding domain of C/EBPα (inhibition of cyclin-dependent kinase 2 activity is another
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mechanism by which C/EBPα acts on the cell cycle) were normal (6). The importance of
PU.1 in terminal myeloid differentiation suggests that a similar role for PU.1 as C/EBPα,
in regulating the cell cycle, may exist.

1.10 Hypothesis
The increased proliferation and impaired differentiation of immature myeloid cells in
Sfpi1BN/BN mice implies that PU.1 is necessary for cell cycle exit during myeloid differentiation. In this scenario, when PU.1 levels are decreased, the cell cycle is no longer regulated
and myeloid progenitors continue to expand uncontrollably, resulting in AML. We have
found that PU.1 transcript levels are inversely correlated with the cell cycle regulator,
E2F1. E2F1 functions to promote G1 to S phase progression, and deregulation of E2F1 is
associated with cancer. This suggests that PU.1 regulates cell cycle at least in part by repression of E2f1 expression. Consistent with the idea that PU.1 represses E2F1 is the fact
that PU.1 levels increase during myeloid terminal differentiation, when cell cycle exit must
occur (6, 50, 87, 88).
In conclusion, I intend to investigate the precise mechanism of how PU.1 works to
regulate proliferation and differentiation of hematopoietic stem cells (HSCs) and its role
in the development of AML. In order to conduct these investigations, I have formed the
following hypothesis:
We hypothesize that PU.1 represses E2F1 to regulate cell cycle exit in myeloid cells.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Mouse Strains
Our laboratory has generated a novel hypomorphic allele of Sfpi1 termed BN,
which produces PU.1 at 20% of wild-type levels (102). Sfpi1+/BN mice were maintained as
an Sfpi1+/BN colony in the West Valley Barrier facility at Western University (London, Ontario, Canada). Sfpi1+/BN mice were mated to breed Sfpi1BN/BN neonates. Animal husbandry
and breeding were conducted in compliance with the University of Western Ontario
Animal Care and Veterinary Services Standard Operating Procedures. Polymerase Chain
Reaction (PCR) was used to genotype mice in colony using primers listed Table 2.1.

2.2 Cell Culture
Complete media contained 10% fetal bovine serum (FBS) (Wisent, St-Bruno,
QC), penicillin (100 U/ml)/streptomycin (100 μg/ml) (Mediatech, Manassas, VA), Lglutamine (0.292 mg/ml) (Mediatech), 2-mercaptoethanol (5 x 10-5 M) (Sigma-Aldrich,
St. Louis, MO), and HEPES (5 mM) (Sigma-Aldrich). GP + E-86 packaging cells and
platinum-E (Plat-E) retroviral packaging cells were both grown in complete Dulbecco’s
Modification of Eagle’s Medium (DMEM) medium (Mediatech). BN cells were grown in
complete Iscove’s Modification of DMEM medium with L-glutamine and 25 mM Hepes
(Mediatech). The cytokine GM-CSF (1 ng/ml) was added.

2.3 Generation of Inducible System
The Retro-X Tet-On 3G Inducible Expression System was purchased from Clontech (Mountain View, CA). In order to clone our gene of interest (PU.1) into the Clontech
response vector (pRetroX-TRE3G vector), an additional EcoR1 site was first added to the
PU.1 cDNA sequence part of the MIG-PU.1 vector using PCR (primer sequences listed
in Table 2.1). Following amplification, the PCR product was cloned into the StrataClone
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Table 2.1 PCR and RT-qPCR primer sequences.

Primer Name

Sequence

PCR  genotyping
Sfpi1 Primer 1
5’ CGGCCAGAGACTTCCTGTAG-3’
Sfpi1 Primer 2
5’-AAGTTGGCCGCAGTGTTATC-3’
Sfpi1 Primer 3
5’-GCTCTTCGTCCAGATCATCC-3’
Sfpi1 Primer 4
5’-ATGGTCACACATCCCAAAGC-3’
PCR – addition of EcoR1 site
3XFLAG EcoR1 forward 5’-GGAATTCGCCGCCATGGACTACAAAGAC-3’
3XFLAG EcoR1 reverse
5’-GGAATTCGTTGGGCCCTCTAGATC-3’
PCR – addition of Bg1II and EcoR1 sites
TET3Gfwd-ATG-Bg1II
5’-ACGTAGATCTATGTCTAGACTGGACAAGAGCAAAGTC-3’
TET3Grev-TAA-EcoRI
5’ACGTGAATTCTTACCCGGGGAGCATGTC3’
qPCR
E2f1 cDNA forward
5’-TCCCTGGGGAGTTCATCAGC-3’
E2f1 cDNA reverse
5’-CTAATGCCCTCACCCTCCTCG-3’
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PCR Cloning Vector (pSC-A-amp/kan) (Agilent Technologies, La Jolla, CA) in order to
enhance the efficiency of restriction enzyme cutting and thus the generation of EcoR1
5’ overhangs. The PCR product is able to be cut out of the pSC-A-amp/kan vector with
100% efficiency due to the supercoiled nature of the vector and the PCR product’s location within the vector. StrataClone SoloPack competent bacteria cells were used in the
transformation to clone the PU.1 PCR product into the pSC-A-amp/kan vector. Following
confirmation that the PU.1 PCR product had been successfully cloned into the pSC-Aamp/kan vector, the entire product was retransformed in preparation for maxi-prep. The
entire product was then maxi-prepped in order to amplify and produce high DNA yields.
The pRetroX-TRE3G vector was then digested with EcoR1 in preparation for ligation of
insert. Following maxi-prep and using EcoR1, PU.1 was excised from the pSC-A-amp/
kan vector and ligated into the pRetroX-TRE3G vector using T4 DNA ligase. Ligated
vector and insert were transformed and bacteria colonies were assessed for successful
cloning of insert into vector using sequencing (to ensure insert was in correct orientation).
Once successful cloning had been established the pRetroX-TRE3G vector with PU.1
cDNA insert was once again retransformed, maxi-prepped and sequenced.
The regulator vector consisted of the Tet-On 3G transactivator genomic fragment
cloned into the MIGR1 vector. Bg1II and EcoR1 restriction sites were PCR amplified
(using primers listed in Table 2.1) into the Tet-On 3G gene, part of the pRetroX-Tet3G
vector. The Tet-On 3G gene was then PCR amplified out of the pRetroX-Tet3G vector
using TET3Gfwd-ATG-Bg1II and TET3Grev-TAA-EcoRI primers (listed in Table 2.1).
The MIGR1 plasmid was digested with EcoR1 and Bg1II and the Tet-On 3G gene was
inserted into the MIGR1 plasmid by sticky end ligation. Separate response and regulator
retroviral supernatants were produced (see below).

2.4 Retrovirus Production
Platinum-E (Plat-E) retroviral packaging cells were used to generate retroviral su-
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pernatants using polyethylenimine (PEI) transfection. Twenty-four hours before transfection, Plat-E cells were plated at a concentration of 5 x 106 cells in a 10 cm Petri dish and
incubated at 37°C overnight. The next day, media (DMEM complete) was removed and
replaced with 10 ml of fresh, serum-free media. Cells were incubated in the serum-free
media for two hours at 37°C prior to transfection. For transfection, 1 ml of serum-free
DMEM complete with 150 mM of NaCl, 1 μg of pCL-Eco plasmid, and 9 μg of DNA of
interest were mixed and vortexed for 15 seconds. Following vortex, 25 μl of PEI (1 μg /
μl) (Polysciences, Warrington, PA) was added to the mixture, the mixture was vortexed
and the entire solution was incubated at room temperature for 20 minutes without disturbance. Finally, 1 ml of the DNA/PEI solution was added to Plat-E cells, followed by 1 ml
of DMEM complete media to ensure cells were not serum starved overnight. Transfected
cells were incubated overnight at 37°C. All media was removed the next morning and
replaced with 2 ml of DMEM complete. Retrovirus-containing supernatant was harvested
48 hours post transfection.

2.5 Retroviral Transduction of BN cells
BN cells were infected by resuspension in cell-free retroviral supernatants and
centrifugation at 3100 rpm for 3 hours in the presence of polybrene (10 μg /ml). Following centrifugation retroviral supernatant was removed and 1 ml of fresh media was added.
Cells were incubated for 48 hours post infection to allow retroviral integration and protein expression.

2.6 Cell Cycle Analysis
The BD Pharmingen BrdU Flow Kit was purchased from BD Biosciences (Mississauga,
ON, Canada). Bromodeoxyuridine (BrdU) incorporation was measured by flow cytometry with an allophycocyanin (APC ) BrdU Flow Kit according to the manufacturer’s
protocol. Briefly, cells were labeled with BrdU for 6 hours at 37°C. Cells were incubated
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with the APC-conjugated anti-BrdU antibody using a 1:800 fold dilution. Staining with
7-amino-actinomycin D (7-AAD) was also conducted to determine cell cycle position.
For 7-AAD staining, cells were suspended in PBS containing 0.5 M EDTA (pH 8.0) and
0.5 % BSA and then incubated with 7-AAD (BD Pharmingen).

2.7 Real-time PCR
RNA was extracted with TRIzol Reagent (Life Technologies, Carlsbad, CA)
and reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA).
Quantitative PCR (qPCR) was then performed using the iQ SYBR Green Supermix Kit
(Bio-Rad) and Rotor-Gene 6000 (Corbett Life Sciences, Valencia, CA). Relative mRNA
transcript levels were normalized to beta-2-microglobulin (B2M) as a reference gene and
compared between samples using the comparative threshold (Ct) cycle method (135).
Results are presented as the mean and SD of three experiments performed in triplicate.
Primer sequences for E2f1 forward and reverse primers are listed in Table 2.1.

2.8 Immunoblotting
Cells were lysed with 6X Laemmli lysis buffer. Proteins from whole cell lysates
were resolved by SDS-PAGE and transferred to a nitrocellulose membrane (Thermo
Scientific, Waltham, MA) using a Trans-Blot SD Semi-Dry Electrophoretic Transfer
Cell (Bio-Rad). Immunoblotting was performed with polyclonal rabbit anti-PU.1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), polyclonal rabbit anti-E2F1 antibody
(Thermo Scientific), polyclonal goat anti-actin antibody (Santa Cruz Biotechnology),
HRP-conjugated anti-rabbit secondary antibody (Pierce, Rockford, IL, USA) and HRPconjugated anti-goat secondary antibody (Pierce). All antibodies were diluted according
to the manufacturer’s protocol. Immunoreactive proteins were visualized with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific).
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2.9 Transplantation Studies
Non-obese diabetic/severe combined immunodeficient/IL-2 receptor gamma chain
null (NOD/SCID/γc-/-) (NSG) mice received 300 rad of irradiation prior to injection. NSG
mice were used as they are the most immunodeficient xenotransplantation model to date
(136). NSG mice not only lack T and B cells (like the NOD/SCID mouse), but also have
defects in NK cell activity, macrophage function, complement activity, and dendritic cell
function (136). The immunodeficiency of NSG mice means they lack the ability to reject
foreign tissue (136), making them strong candidates for transplantation (136). Irradiation was given to further deplete recipient bone marrow cells. Each NSG recipient mouse
received 1 x 106 cells via tail vain injection. In separate experiments, recipient mice
received either spleen cells from Sfpi1BN/BN mice, or cultured BN cells (cell line derived
from Sfpi1BN/BN fetal liver progenitors, as previously described (102)).
Spleens were removed from 3-week-old, Sfpi1BN/BN neonates, homogenized, and
subject to ACK (Ammonium-Chloride-Potassium) lysing buffer to remove erythrocytes.
Spleen cells (splenocytes) were then washed three times in phosphate-buffered saline
(PBS) (Lonza, Walkersville, MD). 1 x 106 splenocytes were resuspended in 500-700 μl of
PBS and kept on ice in preparation for transplant.
Cultured BN cells were washed three times in PBS. 1 x 106 BN cells were resuspended in 500-700 μl of PBS and kept on ice in preparation for transplant.
Post transplantation, mice were monitored for symptoms of disease, specifically
laboured breathing and scruffy appearance. When it appeared that the mouse was likely
to die within 1-2 days, the mouse was euthanized via CO2 overdose. Following euthanasia, recipient spleens were analyzed via flow cytometry.

2.10 Flow Cytometry
Single-cell suspensions from spleens of recipient mice were analyzed by flow
cytometry, as well as single-cell suspensions of cultured BN cells. Single-cell suspen-
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sions were washed in PBS containing 0.5 M EDTA (pH 8.0) and 0.5 % BSA prior to flow
cytometry analysis. Cells were analyzed on a FACSCalibur (BD, Franklin Lakes, NJ).
Antibodies directly conjugated to phycoerythrin (PE), fluorescein isothiocyanate (FITC),
or peridinin-chlorophyll protein with cyanine dye (PerCP-Cy5.5) against the following
markers were used: Mac-1/CD11b (M1/70), c-Kit/CD117 (2B8), FcγRII/III/CD32/CD16
(2.4G2), B4/CD19 (1D3), Ki-67 (MKI67). For Gr-1/Ly-6C (8C5) the primary antibody
was conjugated to biotin and detected using streptavidin-PE secondary antibody. Analysis
was performed using FlowJo version 9.3.2 (Ashland, OR) according to standard protocols. Gates on viable cells were set according to forward and side light scatter, as well as
the exclusion of propidium iodide staining. Fluorescence activated cell sorting (FACS)
was performed for transduced BN cells at the London Regional Flow Cytometry Facility
(Robarts Research Institute) (London, Ontario, Canada) using a FACSAria III flow cytometer using the blue laser (488 nm) for green fluorescent protein (GFP) positive cells.

2.11 Statistical Analysis
Statistical significance was determined by unpaired, two-tailed Student’s t-test or
one-way ANOVA and Tukey’s Multiple Comparison Test using GraphPad Prism v.6. Differences were considered significant with a p-value <0.05.
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CHAPTER 3: RESULTS
3.1 Sfpi1BN/BN spleen cells do not propagate in culture
We have previously shown that Sfpi1BN/BN fetal liver cells can be cultured indefinitely in GM-CSF, whereas Sfpi1BN/+ and Sfpi1+/+ fetal liver cells cannot (unpublished
data). We therefore wanted to establish whether the same would be true of Sfpi1BN/BN
spleen cells, compared to their Sfpi1BN/+ or Sfpi1+/+ counterparts. In order to determine
whether Sfpi1BN/BN spleen cells could be propagated in culture, Sfpi1BN/BN spleen cells were
obtained from a neonatal Sfpi1BN/BN mouse (as well as a Sfpi1BN/+ littermate) and 10, 000,
000 cells from each mouse were placed into 10 ml of media containing the growth factor GM-CSF (1 ng/ml). Cells were passaged every 2-3 days and viable cell counts were
recorded at each passage. At the first passage, the number of both Sfpi1BN/BN and Sfpi1BN/+
spleen cells had dropped dramatically to just over 1, 000, 000 cells (Figure 3.1). By the
second passage, viable cell counts decreased further to ~500, 000, and a little over 300,
000 at the third passage for both Sfpi1BN/BN and Sfpi1BN/+ spleen cells (Figure 3.1). The
experiment was repeated three times and two of the three times all spleen cells from both
the Sfpi1BN/BN and Sfpi1BN/+ were dead by the fourth passage (Figure 3.1). In one of the experiments, the spleen cells from the Sfpi1BN/BN mouse, but not the heterozygote littermate,
were able to grow past the fourth passage (up to passage number eight) but cell counts
remained extremely low (data not shown). This experiment showed that Sfpi1BN/BN spleen
cells cannot be cultured, and thus colony forming assays could not be performed using
these cells.

3.2 The effect of G-CSF on BN cell differentiation and growth
As mentioned, our laboratory has created a novel hypomorphic allele of Sfpi1
termed BN, which produces PU.1 at 20% of wild-type levels (102). Sfpi1+/BN mice were
mated to breed Sfpi1BN/BN neonates. We have also generated a cultured cell line from

Figure 3.1 Sfpi1

BN/BN

spleen cells do not propagate in culture. Spleen cells were ob-

tained from a neonatal Sfpi1BN/BN mouse (as well as Sfpi1+/BN littermate) and 10 000 000
cells from each mouse were placed into culture containing GM-CSF (1 ng/ml). Cells were
passaged and counted every 2 -3 days until all cells were dead and experiment was terminated. Cell counts were recorded at start of experiment and each passage. Black bars
represent spleen cells from Sfpi1BN/BN mouse. Results are presented as the mean + SD of
three experiments (n=3).

37

38

BN
LM

1.0×1007

5.0×1006

Passage number

4

3

2

1

0.0

Start

Cell count

1.5×1007

39
Sfpi1BN/BN mice. The cell line is derived from Sfpi1BN/BN fetal liver progenitors (102). The
cell line is referred to as BN (102). BN cells are cultured in the growth factor, GM-CSF,
as they are a GM-CSF dependent cell line (unpublished data). They have also been shown
to thrive in interleukin-3 (IL-3) (102).
Previous work by Panopoulos et al. showed that the cytokine G-CSF is capable of
stimulating a pathway dependent on Stat3, a major G-CSF responsive signaling protein
(137), that may result in the differentiation of myeloid cells. As a result, we attempted to
assess the differentiation potential of cultured BN cells as a result of G-CSF by culturing
them with or without G-CSF (10 ng/ml). In order to determine whether or not differentiation had occurred as a result of G-CSF treatment, we analyzed expression of the myeloidspecific, terminal differentiation cell surface marker CD11b (107). We also analyzed
expression of the cell surface marker, c-Kit, which is a marker of myeloid progenitor cells
(12). We hypothesized that if BN cells were able to differentiate as a result of exposure to
G-CSF, CD11b would be up-regulated in BN cells grown with G-CSF compared to those
grown without G-CSF. Furthermore, BN cells grown in G-CSF that had differentiated
would down-regulate c-Kit. We cultured 4, 000, 000 BN cells in one of the following cytokine conditions: GM-CSF (10 pg/ml) alone, or GM-CSF (10 pg/ml) and G-CSF (10 ng/
ml), and analyzed for CD11b and c-Kit expression via flow cytometry after 3 days of culture. Our results showed that there was no difference in either CD11b or c-Kit expression
between BN cells grown with or without G-CSF (Figure 3.2). There was no significant
difference (p = 0.5537) between mean fluorescence for CD11b of BN cells grown without
G-CSF (black bar, Figure 3.2 B) versus those grown with G-CSF (grey bar, Figure 3.2 B).
There was also no significant difference (p = 0.9346) between mean fluorescence for cKit of BN cells grown without G-CSF (black bar, Figure 3.2 D) versus those grown with
G-CSF (grey bar, Figure 3.2 D). Therefore, our data suggests that G-CSF does not induce
differentiation of BN cells based on the expression of the terminal differentiation marker
CD11b, and the immature, progenitor marker, c-Kit.

Figure 3.2 BN cells cultured in G-CSF do not up-regulate expression of CD11b or
down-regulate expression of c-Kit. Cultured BN cells were grown in media containing
either GM-CSF (10 pg/ml) alone, or a combination of GM-CSF (10 pg/ml) and G-CSF
(10 ng/ml). Following 3 days of culture, cells were analyzed by flow cytometry for expression of cell surface markers. (A) Histogram shows expression of CD11b, a myeloidspecific cell surface marker, for BN cells grown in GM-CSF alone (black), or a combination of GM-CSF and G-CSF (grey). (B) Bar graph shows the mean fluorescence of
CD11b expression for BN cells grown in GM-CSF alone (black bar), or BN cells grown
in GM-CSF and G-CSF (grey bar). (C) Histogram shows expression of c-Kit, a cell surface marker of myeloid progenitor cells, for BN cells grown in GM-CSF alone (black),
or a combination of GM-CSF and G-CSF (grey). (D) Bar graph shows the mean fluorescence of c-kit expression for BN cells grown in GM-CSF alone (black bar), or BN cells
grown in GM-CSF and G-CSF (grey bar). Histograms are representative images from one
of three experiments (n=3), while bar graphs are presented as the mean + SD of the three
experiments.
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We next investigated whether or not BN cells, a GM-CSF dependent cell line
(unpublished data), could also be grown in G-CSF. We cultured 100 000 BN cells in one
of the following cytokine conditions: GM-CSF (1 ng/ml) alone, GM-CSF (1 ng/ml) and
G-CSF (10 ng/ml), or G-CSF (10 ng/ml) alone, and measured their proliferation after 4
days of culture. Cultured BN cells grown in GM-CSF alone or the combination of GMCSF and G-CSF grew equally well; both showed over 20-fold expansion (Figure 3.3).
Nonetheless, there was no significant difference (p = 0.8142) between BN cells grown
in GM-CSF alone or the combination of GM-CSF and G-CSF. In contrast, cells grown
in G-CSF only were unable to proliferate (Figure 3.3). BN cells grown in GM-CSF only
proliferated significantly more than BN cells grown in G-CSF only (p = <0.0001) (Figure
3.3, ****). BN cells grown in the combination of GM-CSF and G-CSF also proliferated significantly more than BN cells grown in G-CSF only (p = 0.0170) (Figure 3.3, *).
Therefore, our data illustrates that BN cells are not responsive to G-CSF. G-CSF did not
permit growth when used exclusively, but could be used in combination with GM-CSF.
However, the combination of growth factors did not increase proliferation compared to
GM-CSF used independently.

3.3 Co-culture with retroviral producing cells does not allow effective restoration of
PU.1 expression
In order to test the hypothesis that restoration of PU.1 expression in cultured BN
cells would result in cell cycle exit, reduced proliferation and ultimately differentiation,
cultured BN cells were co-cultured with mitomycin C treated GP + E86 packaging cells,
a retroviral producing cell line (Figure 3.4A). GP +E86 packaging cells were treated with
mitomycin C to prevent proliferation. BN cells were grown in the presence of GP + E86
cells producing a previously constructed retrovirus (termed MIG-PU.1) that expresses
a 3X-FLAG tagged PU.1 gene, as well as the marker GFP. As a control, BN cells were
grown in the presence of GP + E86 cells producing an empty retroviral vector, (termed
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Figure 3.3 The cytokine G-CSF does not enable nor inhibit growth of cultured BN
cells. Cultured BN cells were grown in media containing either GM-CSF (1ng/ml) alone
(hatched bar), a combination of GM-CSF (1 ng/ml) and G-CSF (10 ng/ml) (black bar), or
G-CSF (10 ng/ml) alone (white bar). 100 000 cells were plated in each cytokine condition
and cell counts were taken following 4 days of culture. Results are presented as the mean
+ SD of one experiment (n=1) performed in triplicate. Significant differences are indicated with asterisk (*).
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MIGR1) where PU.1 was not introduced. The MIGR1 retroviral vector still expresses
GFP. BN cells were cultured in direct contact with the retrovirus producing cells for 3
days before they were transferred to a second co-culture with fresh retroviral packaging
cells. Following the two rounds of retroviral transduction, we attempted to select for BN
cells where PU.1 expression had been restored, by culturing cells in media containing
GM-CSF, as well as M-CSF. While BN cells are known to express the GM-CSF receptor, they do not express the M-CSF receptor. However, PU.1 activates expression of the
M-CSF receptor (104) and theoretically, BN cells that successfully take up the MIGPU.1
retrovirus should be able to respond to stimulation with M-CSF and grow in the presence
of M-CSF while uninfected cells should not (Figure 3.4A). As mentioned, MIG retroviruses are tagged with GFP and retrovirally infected BN cells will be GFP positive. The
highest transduction frequencies achieved using the co-culture method are illustrated in
Figure 3.4B. While transduction frequencies were able to reach a relatively high level,
this did not occur consistently. Furthermore, infected BN cells that were recovered after
selection in M-CSF were mostly dead based on trypan blue cell counting.

3.4 Inducible expression system enables restoration of PU.1, up-regulation of PU.1
target genes and differentiation
In order to assess the effect of PU.1 restoration on BN cells before cell death, we
developed a technique in which we could systematically induce PU.1 expression. The
system exploited two separate retroviral vectors, termed the regulator and the response.
The regulator vector encoded the Tet-On 3G transactivator protein, as well as GFP (Figure 3.5A). The response vector contained the gene encoding PU.1 under the control of
a TRE3G promoter (PTRE3GV), as well as a puromycin resistance gene (Figure 3.5A).
In the presence of doxycycline (Dox), Tet-On 3G binds specifically to PTRE3GV and
activates transcription of downstream PU.1. In order to set up the system, cultured BN
cells were infected with the regulator and response retroviruses simultaneously (Figure
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Figure 3.4 Infection of BN cells via co-culture. (A) Schematic of co-culture method
used to restore PU.1 expression in BN cells. BN cells, a GM-CSF dependent cell line,
were cultured in the presence of mitomycin C treated, GP + E86 packaging cells producing either MIGR1 or MIGPU.1 retrovirus for 3 days, after which they were transferred
into a second culture of fresh GP + E86 packaging cells. Following the second 3-day coculture, BN cells were transferred to media containing GM-CSF (10 pg/ml) and M-CSF
(10 ng/ml) to select for infected cells. (B) Highest infection frequencies reached for BN
cells infected with either MIGR1 (left panel) or MIGPU.1 (right panel) retrovirus using
the co-culture technique. Open histograms show expression of green fluorescent protein
(GFP). Black histograms represent negative (uninfected) cells. Histograms are representative images from one of three experiments (n=3); the percentage of infected BN cells
+/- SD of the three experiments is listed in the top right hand corner.
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Figure 3.5 Construction of inducible system used to restore expression of PU.1. (A)
Two separate retroviral vectors were used in the inducible system. The regulator vector
contains the Tet-On 3G transactivator protein, which in the presence of doxycycline is
able to bind and activate expression of the PTRE3G inducible promoter. The PTRE3G
promoter controls expression of PU.1 and is located in the pRetroX-TRE3G response
vector. A selectable marker was also part of each vector. The regulator vector contains the
gene encoding GFP and the response vector contains a puromycin resistance gene. (B)
Cultured BN cells were infected with both regulator and response retroviral vector supernatants simultaneously via spin infection. Following infection, BN cells were cultured
in media containing puromycin to select for BN cells that had successfully taken up the
response vector containing the puromycin resistant gene. Puromycin resistant cells were
then screened for GFP positivity using a combination of cloning and cell sorting to select
for cells that also contained the regulator vector. Finally doxycycline was added at a
concentration of 1000 ng/ml to BN cells infected with both regulator and response retroviruses, effectively turning on PU.1 expression.
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3.5B). Infected cells were selected by growth in the presence of puromycin (Figure 3.6A).
Puromycin resistant cells were also screened for GFP positivity by flow cytometry. FACS
for GFP expression was conducted to enrich a population of purified GFP positive cells
(Figure 3.6B,D). The presence of the Tet-On 3G protein was confirmed in selected cells
by immunoblot using the TetR monoclonal antibody (Figure 3.6C). GFP positive, puromycin resistant BN cells were then grown in culture with doxycycline (1000 ng/ml) to
induce PU.1 expression (Figure 3.5B). BN cells successfully infected with both retroviral
vectors expressed high levels of PU.1, when cultured in the presence of doxycycline, as
confirmed by immunoblot (Figure 3.7A). Finally, CD11b expression was analyzed by
flow cytometry in dox induced versus non-induced cells. CD11b is directly activated by
PU.1 (107) and therefore PU.1 reintroduction should result in an up-regulation of CD11b
expression. As well, CD11b is a cell surface marker, specific to mature myeloid cells
(107) and indicates differentiation. As expected, CD11b was up-regulated in dox induced
BN cells compared to non-induced cells (Figure 3.7B). Thus, following PU.1 restoration,
BN cells showed signs of differentiation by expressing a terminal differentiation marker,
CD11b.

3.5 Restoration of PU.1 expression in cultured BN cells results in reduced
proliferation and cell cycle exit at the G0/G1 phase
Once PU.1 restoration was established, we assessed the biological effect of
restoration in cultured BN cells. In order to address the hypothesis that PU.1 restoration
will allow immature progenitors to exit the cell cycle and differentiate, we looked at the
ability of BN cells to grow over 4 days of culture, in the presence of various concentrations of doxycycline. At a concentration as low as 100 ng/ml, induction resulted in a
decrease in cell proliferation, compared to untreated control (Figure 3.8). The cell count
was significantly lower (p < 0.05) (Figure 3.8, *) for regulator and response infected BN
cells grown in the presence of doxycycline (100 ng/ml) than infected BN cells grown in
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Figure 3.6 Selection of BN cells infected with both regulator and response retroviral
supernatants. (A) Selection of BN cells successfully infected with the response vector.
(+) indicates retroviral infected BN cells. (-) indicates uninfected BN cells. Cells able to
grow in the presence of puromycin contain the response vector (n=1). (B) Selection of
BN cells successfully infected with the regulator vector (n=1). GFP positive cells indicate
the presence of the regulator vector. The histogram shows expression of GFP. Red represents negative (uninfected) BN cells. Blue represents regulator and response infected
BN cells. (C) An immunoblot was conducted to confirm the presence of the Tet-On 3G
transactivator protein in GFP positive cells using the TetR monoclonal antibody (n=1).
b-actin served as a control. (D) Using fluorescence microscopy, an image was taken of
puromycin resistant, GFP+ve BN cells (n=1).
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Figure 3.7 Restoration of PU.1 expression and up-regulation of CD11b following
induction. (A) An immunoblot was conducted using anti-PU.1 antibody to demonstrate
PU.1 restoration following induction with doxycycline (1000 ng/ml) (n=1). An anti-actin
antibody was used as a control. (B) Flow cytometry on induced BN cells, 5 days following doxycycline (1000 ng/ml) induction. The histogram shows expression of CD11b, a
direct target of PU.1. Open histogram represents non-induced BN cells while filled black
histogram represents CD11b expression after doxycycline treatment of BN cells. Histogram is a representative image from one of three experiments (n=3).
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Figure 3.8 Restoration of PU.1 expression following induction by doxycycline results in a block in proliferation. Cell growth of retrovirally infected BN cells at various
concentrations of doxycycline (black bars). Uninfected BN cells (white bars) were grown
in the presence of doxycycline (1000 ng/ml) as a control for possible growth inhibition by
doxycycline. Results are presented as the mean and SD of three experiments (n=3). Cell
growth at each different doxycycline concentration of retroviral infected BN cells was
compared to cell growth of infected BN cells grown in the absence of doxycycline, following 4 days of culture. Significant differences are indicated with asterisk (*).
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the absence of doxycycline (Figure 3.8). There was a gradual reduction in cell counts as
the concentration of doxycycline increased (Figure 3.8). To eliminate the possibility that
the doxycycline was toxic to the cells, we grew uninfected BN cells in the presence of a
high concentration of doxycycline (1000 ng/ml) (Figure 3.8). The cell counts were not
significantly different (p > 0.05) between uninfected BN cells grown in the presence of
doxycycline (1000 ng/ml) and those grown in the absence of doxycycline (Figure 3.8),
which indicated that the concentration of doxycycline being used for induction was not
toxic. These results suggest that increased PU.1 expression might be promoting cell cycle
exit or apoptosis.
The reduction in proliferation following PU.1 restoration prompted investigation
into the cell cycle. Cell cycle analysis was conducted using BrdU and 7-AAD to identify
cells actively synthesizing DNA during the different stages of the cell cycle (G0/G1, S, or
G2/M). This technique permits quantification of the frequency of cells in each phase of
the cell cycle. Doxycycline induced cells were mostly apoptotic (47.5%) (Figure 3.9B).
Importantly, more non-induced cells were in S phase (52.5%), compared to doxycycline
induced cells (25.2%) (Figure 3.9C,D), implying a block in the G1 to S phase transition
following PU.1 restoration. These results suggest that PU.1 restoration results in cell
cycle exit, specifically at the G1 to S phase transition.

3.6 PU.1 regulates the cell cycle by repressing E2F1
Previous work in our lab determined an inverse relationship between PU.1 expression and the cell cycle regulator E2F1 (unpublished data). In Sfpi1BN/BN mouse spleen
cells, where PU.1 levels were reduced, E2F1 levels were increased compared to Sfpi1BN/+
mice (unpublished data). Our cell cycle analysis results support this finding as E2F1
functions in the transition from G1 to S phase (126). As a result, we hypothesized that
PU.1 regulates the cell cycle via repression of E2F1. To test this hypothesis, we examined whether E2f1 transcript and E2F1 protein was reduced following PU.1 restoration in

Figure 3.9 PU.1 restoration blocks G1 to S phase transition. Cell cycle analysis was
conducted to determine the position of cells within the cell cycle. Cycling of non-induced
BN cells (white) was compared to doxycycline induced BN cells (black). (A) Gating
strategy used (gating of non-induced cells is shown); G1 represents apoptotic cells; G2
represents live cells. (B) Quantification of the percentage of apoptotic (G1) and live (G2)
cells under the two conditions (non-induced (white) compared to doxycycline induced
(black) BN cells). (C) BrdU incorporation was measured by flow cytometry on G2 cells
in non-induced BN cells (white) and doxycycline induced BN cells (black). (D) Quantification of the percentage of cells in S phase as indicated by BrdU incorporation for noninduced BN cells (white) and doxycycline induced BN cells (black).
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cultured BN cells. Reverse transcriptase qPCR (RT-qPCR) analysis demonstrated a 3.1
fold reduction in E2f1 transcripts in BN cells where PU.1 expression had been restored
(Figure 3.10). Western blot analysis confirmed a substantial reduction in E2F1 protein in
doxycycline induced BN cells compared to non-induced cells (Figure 3.11). In conclusion, our results establish PU.1 as a repressor of E2f1 gene expression.

3.7 The spleens of Sfpi1BN/BN mice contain a population of highly proliferative,
myeloid cells
As described in the introduction, our laboratory has developed a mouse model in
which mice homozygous for the Sfpi1 BN allele produce PU.1 at 20% of wild-type levels
(102). Mice homozygous for Sfpi1 allele (Sfpi1BN/BN mice) also demonstrated hyperproliferation of immature myeloid cells in the bone marrow, spleen and other tissues (102).
To demonstrate increased proliferation in the spleens of Sfpi1BN/BN mice, flow cytometric
analysis was performed for the nuclear protein Ki-67, as well as the myeloid specific
cell surface marker CD11b. Ki-67 is highly expressed in proliferative cells; it is present
during active cell cycle but absent from resting cells (138). Flow cytometric analysis was
performed using single-cell suspensions from the spleens of 21-day Sfpi1BN/BN and Sfpi1+/+
mice. There was an up-regulation of both CD11b and Ki-67 in Sfpi1BN/BN spleen cells
compared to Sfpi1+/+ mice (Figure 3.12). In the representative images, the mean fluorescence intensity of Ki-67 expression in Sfpi1BN/BN spleen cells was 752 compared to 459 in
Sfpi1+/+ spleen cells (Figure 3.12). Flow cytometric analysis of Sfpi1BN/BN spleens demonstrated an increase in the frequency of myeloid, proliferative cells compared to littermate
control, as indicated by CD11b and Ki-67 expression, respectively (Figure 3.12). These
results suggest that myeloid proliferation is increased in the spleens of Sfpi1BN/BN mice.

3.8 Transplantation studies
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Figure 3.10 E2f1 is down-regulated upon induction of PU.1 with doxycycline. RTqPCR was performed to determine relative frequencies of E2f1 transcripts in doxycycline
induced BN cells compared to non-induced BN cells. RNA was prepared from retroviral
infected BN cells cultured in the presence of doxycycline (1000 ng/ml) and absence of
doxycycline. Fold change is shown in reference to the housekeeping gene beta-2-microglobuliin (B2M). Results are presented as the mean + SD of three experiments (n=3)
performed in triplicate. Significant differences are indicated with asterisk (*).
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Figure 3.11 E2F1 protein level is decreased upon induction of PU.1 with doxycycline.
An immunoblot was conducted using anti-E2F1 antibody to demonstrate E2F1 repression
by PU.1 following PU.1 restoration with doxycycline (1000 ng/ml) (n=1). As a control an
immunoblot was conducted using anti-actin antibody.
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Figure 3.12 Sfpi1

BN/BN

myeloid cells are increased in frequency in vivo. The spleens of

21-day Sfpi1BN/BN mice (right panels) contain a proliferative (Ki-67high), myeloid (CD11b+)
population that is increased compared to wild-type (wt) littermates (left panels). Flow-cytometric analysis of CD11b, a myeloid-specific cell surface marker, and Ki-67, a nuclear
protein highly expressed in proliferative cells, was performed using single-cell suspensions from the spleens of 21-day Sfpi1BN/BN or Sfpi1+/+ mice. Flow-cytometric analysis of
single-cell suspensions from the spleens of 21-day Sfpi1BN/BN mice (right panels) demonstrates a larger population of CD11b+ myeloid cells (top) as well as an upregulation of
Ki-67 (bottom), in comparison to Sfpi1+/+ mice (left panels). Histograms are representative images from one of two experiments (n=2); the percentage of CD11b +/- SD cells of
the two experiments is listed in the top two plots. The mean fluorescence (MF) of Ki-67
expression of the representative image is listed in the bottom two plots.
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In order to determine whether reduced expression of PU.1 in Sfpi1

BN/BN

myeloid

cells is sufficient to cause the development of AML in mice, transplantation studies were
conducted. NSG mice were each injected with either 1 x 106 splenocytes from Sfpi1BN/
BN

mice, or cultured BN cells. Recipient mice were monitored for symptoms of AML and

when a mouse showed laboured breathing and scruffy appearance (likely to die within
1-2 days), the mouse was euthanized and the morphology of the spleen was analyzed,
as highly enlarged spleens are characteristic of leukemic mice (Figure 3.13). Single cell
suspensions were prepared from the spleens of recipient mice and analyzed for engraftment and myeloid cell composition by flow cytometry. In order to conclude that mice
have become sick due to AML, a population of immature, myeloid cells must be present.
To verify the composition of cells, CD11b and c-Kit were used. As previously mentioned,
c-Kit is expressed at high levels in immature progenitors (12), while CD11b is a cell
surface marker of the myeloid lineage (107). Other myeloid cell surface markers, such as
Gr-1 and FcγRII/III were also analysed. CD19, a B cell-specific marker (139) was also
examined to exclude the possibility of a B cell leukemia. The cell surface marker CD45.2
was used for donor cells from Sfpi1BN/BN mice to indicate whether or not engraftment took
place. CD45.2 is expressed on the surface of donor cells (Figure 3.14A) but not in the
recipient NSG mice; whereas NSG mice express the CD45.1 cell surface marker (Figure
3.14A). Because the cultured BN cell line did not express CD45.2 (Figure 3.16A), we
generated a line of GFP +ve BN cells (Figure 3.16B), used to determine the origin of the
cell population present in recipient mice for transplant work with the cultured BN cells.
NSG mice transplanted with Sfpi1BN/BN spleen cells (n = 6) had a median survival
of 50 days (Figure 3.13A), while NSG mice transplanted with cultured BN cells (n = 8)
had a median survival of 90.5 days (Figure 3.13B). A large population of immature (cKit+), myeloid (CD11b+, CD19-) cells was present in the spleens of NSG mice injected
with Sfpi1BN/BN spleen cells (Figure 3.15 A, B, C, middle panels) or BN cells (Figure 3.15
A, B, C, right panels), compared to wild-type spleens (Figure 3.15 A, B, C, left panels).
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Figure 3.13 NOD/SCID/γc mice transplanted with Sfpi1BN/BN splenocytes or
cultured BN cells become sick and require euthanasia after transplantation. (A)
Survival of NOD/SCID/γc (NSG) mice (n=6) injected with splenocytes from Sfpi1BN/BN.
The median survival was 50 days. (B) Survival of NSG mice (n=8) injected with cultured BN cells. The median survival was 90.5 days.
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Figure 3.14 NOD/SCID/γc mice transplanted with Sfpi1

BN/BN

splenocytes or cultured

BN cells contain a donor-derived population of cells.
Flow cytometric analysis was conducted using single cell suspensions from the spleens
of wild type C57/Bl6 mice, wild type NOD/SCID/γc (NSG) mice, NSG recipient mice
transplanted with Sfpi1BN/BN splenocytes, or NSG recipient mice transplanted with
cultured BN cells. Sfpi1BN/BN splenocytes were isolated from C57/Bl6 Sfpi1BN/BN mice.
Sfpi1BN/BN splenocytes and cultured BN cells were isolated and transplanted by tail vein
injection into sublethally irradiated NSG recipients. Recipient mice were injected with
1 x 106 cells/recipient mouse.
(A) Donor mice (C57/Bl6) express CD45.2 (grey histograms) while recipient mice
(NSG) express CD45.1 (black histograms). Histograms are representative images from
one of three experiments (n=3). (B) The dot plots show expression of the cell surface
markers CD45.1 and CD45.2. Cultured BN cells did not express either CD45 marker.
Engraftment of Sfpi1BN/BN CD45.2+ donor cells in NSG CD45.1+ recipient mice is shown
in the middle dot blot. Engrafted cultured BN cells are CD45.1- and CD45.2- (right dot
plot).
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Figure 3.15 NOD/SCID/γc mice transplanted with Sfpi1BN/BN splenocytes or
cultured BN cells contain a large population of immature (c-Kit+ve), myeloid
(CD11b+ve, FcγRII/III+ve, Gr-1+ve, CD19-ve) cells, indicative of AML. Flow cytometric analysis was conducted using single cell suspensions from the spleens of WT C57/
Bl6 mice (left panels), NOD/SCID/γc (NSG) recipient mice transplanted with Sfpi1BN/
BN

splenocytes (middle panels), or NSG recipient mice transplanted with cultured BN

cells (right panels). Sfpi1BN/BN splenocytes were isolated from C57/Bl6 Sfpi1BN/BN mice.
Sfpi1BN/BN splenocytes and cultured BN cells were isolated and transplanted by tail
vein injection into sublethally irradiated NSG recipients. Recipient mice were injected
with 1 x 106 cells/recipient mouse. Histograms show expression of c-Kit (A), which is
a cell surface marker of immaturity, CD11b (B) a myeloid-specific cell surface marker,
and CD19, a B cell-specific marker (C). Histograms also show expression of FcγRII/
III (D) and Gr-1 (E), both myeloid cell surface markers. Open histograms represent the
negative (unstained) control. Histogram gating strategies are shown in Figure 3.14 on
the CD45.2+ population (wt C57/Bl6 mice and NSG recipient mice transplanted with
Sfpi1BN/BN splenocytes) and CD45.1- population (NSG recipient mice transplanted with
cultured BN cells). All histograms are representative images.
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Spleen cells of NSG transplanted with either Sfpi1BN/BN spleen cells or BN cells also expressed high levels of FcγRII/III and Gr-1, compared to wild-type spleens (Figure 3.15 D,
E). Engraftment was demonstrated in NSG mice transplanted with Sfpi1BN/BN spleen cells
by the CD45.2 expression of cells present in recipient spleens (Figure 3.14 B middle dot
plot). Engraftment was suggested in NSG mice transplanted with cultured BN cells by the
lack of CD45.1+ cells (Figure 3.14 B right dot plot). Engraftment was confirmed in NSG
mice transplanted with GFP +ve BN cells by the population of cells expressing GFP in recipient spleens (Figure 3.16C). Finally, upon euthanasia, recipient mice had significantly
enlarged spleens (data not shown), a characteristic of AML. Taken together, these results
suggest that NSG transplanted with Sfpi1BN/BN splenocytes or cultured BN cells become
sick with disease resembling AML following transplantation.
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Figure 3.16 Generation of a GFP+ve BN cell line to use in transplantation studies.
(A) Cultured BN cells did not express the CD45.2 cell surface marker (n=1). (B) Cultured BN cells were made GFP+ve using a retroviral infection in order to identify donor
cell population in transplantation studies (n=1). (C) Flow-cytometric analysis was conducted using single-cell suspensions from the spleen of a NOD/SCID/����������������
γc��������������
(NSG) recipient mouse transplanted with cultured GFP+ve BN cells. The right panel shows a GFP+ve
population present in a NSG recipient spleen, demonstrating engraftment (n=1). The
left panel shows the spleen of a NSG injected with non-GFP+ve BN cells (n=1).
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CHAPTER 4: DISCUSSION
4.1 Overview
The goal of this project was to determine the role of PU.1 in cell cycle regulation
and the development of AML. We have shown that a reduction in PU.1 expression resulted
in the development of AML in NOD/SCID/gc mice ~70 days after transplantation. Based
on our in vitro results, we propose that the development of AML in these mice was likely
due to lack of cell cycle exit and terminal differentiation, which corresponds to insufficient
PU.1 levels. Our work demonstrated that restoration of PU.1 expression promotes cell
cycle exit and permits terminal myeloid differentiation. Furthermore, we have elucidated
the mechanism by which cell cycle exit is able to occur; recovered expression of PU.1
resulted in repression of the potent cell cycle activator, E2F1. Taken together, these results
provide strong evidence that PU.1 regulates the cell cycle through repression of E2F1, and
insufficient E2F1 repression due to reduced levels of PU.1 expression results in the development of AML.
4.2 Restoration of PU.1 expression results in decreased proliferation, increased
differentiation, and cell cycle block in G1 to S phase transition
While the phenotype of mice and cultured cells with reduced expression of PU.1
have been previously characterized (47, 102), we sought to determine if the characteristics of these mice and cells could be reversed upon PU.1 restoration. In order to do this,
we used a cell line, derived from the fetal liver cells of Sfpi1BN/BN mice (BN cells). In order to reintroduce PU.1, we employed a retrovirus encoding a PU.1 cDNA that was under
the control of an inducible promoter. This strategy allowed us to precisely induce expression of PU.1 in the presence of doxycycline. Upon induction with doxycycline, proliferation of BN cells decreased dramatically. Furthermore, BN cells in which PU.1 expression
had been restored showed the progression of differentiation by expressing higher levels
of the terminal differentiation marker CD11b. In summary, PU.1 restoration enabled cell
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cycle exit, and induced cell differentiation, demonstrating that myeloid cell proliferation/
differentiation was strictly related to PU.1 levels, implying a role for PU.1 in cell cycle
regulation.
To assess the role of PU.1 in cell cycle progression, we measured 5-bromodeoxyuridine (BrdU) incorporation in combination with 7-amino-actinomycin D (7-AAD)
staining in vitro. BrdU permits identification of cells that are actively synthesizing DNA
while 7-AAD defines cell cycle stage (G0/1, S, or G2/M). We compared cell cycle stage
in PU.1-deficient BN cells versus doxycycline induced BN cells, where PU.1 expression
had been restored. BrdU/7-AAD staining revealed that PU.1-deficient BN cells, were
actively cycling, as evidenced by an increased number of S stage cells. In contrast, doxycycline induced cells had a large proportion of cells that were apoptotic. This experiment
suggests that PU.1 inhibits the G1 to S phase transition, allowing cells to exit the cell
cycle and differentiate. This concept is supported by the role PU.1 plays in terminal myelopoiesis. Several groups have shown that PU.1 levels increase during granulocytic and
monocytic differentiation (47, 87-88, 140). When PU.1 levels are decreased to only 20%
of wild-type levels, as in the BN cell line, cells are deregulated and remain in the cell
cycle, unable to differentiate. This supports the phenotype of Sfpi1BN/BN mice that contain
a highly proliferative, immature myeloid population (102). In summary, a role for PU.1 in
cell cycle regulation is consistent with the necessity of PU.1 in terminal myeloid differentiation. In addition, cells must properly exit the cell cycle for differentiation to occur. Due
to the requirement of PU.1 for terminal myeloid differentiation, it makes sense that PU.1
drives cell cycle exit.
Our results are in agreement with the recently published data of Staber et al. that
shows that PU.1 regulates proliferation in HSCs and that this effect is directly related to
PU.1 levels (141). This group discovered that compared to wild-type mice, the proliferative fraction of HSCs was doubled and there was a substantial increase in S, G2, and M
phase cells in mice expressing reduced levels of PU.1 (141). Importantly, restoration of
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PU.1 levels reversed the S/G2/M fraction to normal levels (141). Of note, the mouse
knock-in model (PU.1 ki/ki) used in the work by Staber et al. (with targeted disruption
within the -14 kb URE of murine PU.1) had unchanged PU.1 levels in the whole bone
marrow compartment, but HSCs specifically demonstrated a PU.1 reduction to 40% of
wild-type levels (141). Comparing this mouse model to that of Rosenbauer et al., which
deleted the entire -14 kb enhancer region of PU.1, shows that the major phenotypic difference between the two strains appeared after the HSC stage, in the myeloid progenitor compartment (47, 141). FACS profile for LIN-SCA+KIT+ HSCs was similar between
strains; the myeloid progenitor profile was completely disturbed in Rosenbauer et al.’s
URE-KO mice, whereas it appeared mostly normal in Staber et al. ‘s PU.1ki/ki mice (47,
141). Furthermore, HSCs of URE KO mice progressed to leukemia whereas PU.1ki/ki mice
did not (47, 141). In comparing our study to that of Staber et al., two important differences emerge between their model and our group; in the Staber et al. model PU.1 expression
was reduced to 40% of wild-type levels (whereas ours was 20%) and reduced PU.1 expression was restricted to HSCs (while our reduction in PU.1 expression was applicable
to all blood cell types, in which PU.1 is normally expressed) (102). Furthermore, Staber
et al. investigated the long-term repopulation potential of HSCs (141), while we looked at
the ability of reduced expression of PU.1 in myeloid progenitors to induce AML. As well,
our mouse model developed leukemia, whereas theirs does not. This suggests that the
reduction in PU.1 expression must be sufficiently low and widespread in order to block
terminal differentiation, leading to the development of AML.
4.3 E2F1 and its role in myeloid proliferation/differentiation
The finding that PU.1 restoration inhibited cell cycle progression, specifically at
the G1 to S phase supported previous unpublished work in our lab that found an inverse
correlation between PU.1 and E2F1 protein levels. E2F1 is a transcription factor that promotes cell cycle progression and S-phase entry (123), by controlling the transcription of
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genes required for cell division (126). Our results showed that following PU.1 restoration,
both transcript and protein levels of E2F1 were down-regulated, indicating a repressive
function for PU.1 on E2F1. In support of a role for E2F1 in the blood cell system, Zhu
and colleagues have reported E2F1 as a regulator of hematopoietic cell proliferation and
differentiation (142). Also, Amanullah et al. have demonstrated that E2F1 is a negative
regulator of myeloid differentiation (143). They showed that deregulated expression of
E2F1 blocked terminal myeloid differentiation, and promoted leukemogenicity in interleukin-6 (IL-6) treated M1 cells in vivo (143). This finding nicely supports our evidence
that reduced PU.1 levels and deregulated E2F1 levels (due to lack of PU.1 repression),
result in the development of AML.
The strength of E2F1 as an activator of genes that are essential for cellular proliferation is highlighted by the fact that E2F1 can override various growth-arrest signals,
including TGF-β and the CKIs p16, p21, and p27, in some situations (144-146). This
finding agrees with the role of E2F1 in cancer development, as deregulation of E2F1 has
been largely implicated in human cancers (125, 130). Not unexpectedly, Rb function is
compromised in most, if not all, of human cancers (130). Binding by Rb to E2F1 inhibits its transcriptional activation capacity (130); thus when Rb function is compromised,
E2F1 is deregulated.
Other myeloid specific transcription factors have also been associated with cell
cycle regulation both positively and negatively. The proto-oncogenes c-myb and cmyc are positive regulators of cell cycle progression (34), while C/EBPα is a negative
regulator and promotes cell-growth arrest by coordinating exit from the cell cycle. C/
EBPα has been shown to inhibit G1 to S phase transition
�������������������������������������������
in myeloid cells (147-148). Perhaps the most important mechanism by which C/EBPα exerts
������������������������������������
its effect is by direct binding to E2F1 where the interaction between C/EBPα and E2F1enables growth inhibition in
myeloid cells and was required for terminal differentiation (149-151). Due to the necessity of both C/EBPα and PU.1 in myelopoieis, it would not be surprising if they both
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shared the ability to promote cell cycle exit via repression of E2F1.
Lastly, Gibbs et al. have shown that the protein product of the PU.1 target gene
Egr-1 is able to abrogate the E2F1 block in terminal myeloid differentiation and consequently suppress leukemia (134). In concordance with the fact that Egr-1 functions as a
tumor suppressor when myeloid differentiation is blocked by E2F1, is the discovery that
the human EGR-1 gene is frequently deleted or subject to monosomy in patients with
myelodysplastic syndromes or AML (152-153). Thus, the tumour suppressor role of Egr1 may represent a strong candidate for differentiation treatment in certain types of leukemias.

4.4 The mechanism by which PU.1 regulates the cell cycle
While we have successfully demonstrated PU.1 repression of E2f1 gene expression, the detailed mechanism by which PU.1 is regulating the expression remains unclear.
PU.1 may directly bind the E2f1 promoter and repress transcription. Alternatively, the
mechanism may be indirect, in which case PU.1 might activate another regulator which
in turn blocks E2f1 transcription.
Support for an indirect mechanism of repression comes from published evidence
that PU.1 activates expression of a microRNA (miRNA), miR223, which then goes on
to disrupt translation of E2F1 protein (154-156). MicroRNAs are noncoding RNA molecules that regulate the expression of target genes by binding imperfectly with regions in
target messenger RNAs (mRNAs) (154). MicroRNAs control gene expression through
both translational repression and degradation of target mRNAs (154). Recently it has
been shown that the primary mechanism of action of miRNAs is translational inhibition
and that this must occur before mRNA may be targeted for degradation (154). PU.1 has
been shown to activate miR223 in the myeloid lineage (155). Pulikkan et al. have demonstrated that miR223 targets and represses E2F1 during granulopoiesis (156). They went
on to report that E2F1 protein was up-regulated in miR223 null mice and that miR223
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blocks cell cycle progression in myeloid cells (156), providing substantial evidence for
the claim that miR223 targets E2F1. Another group has confirmed the role of miR223 in
terminal myeloid differentiation by showing that miR223 knockout mice display defective granulopoiesis (157). Furthermore, miR223 is down-regulated in different subtypes
of AML (156) and miR223 is inactivated by the AML1-ETO fusion oncoprotein, which
is present in many cases of AML (158). All this data supports a pathway by which, under
normal conditions, PU.1 is expressed in myeloid progenitors, resulting in miR223 activation, and subsequent suppression of E2F1, cell cycle arrest at the G1 to S phase boundary, and terminal myeloid differentiation. Conversely, when PU.1 is expressed at reduced
levels, miR223 is not expressed, resulting in deregulated E2F1 protein levels, continual
cell cycle progression of immature myeloid cells, and ultimately AML.
Alternatively, one group has shown, through chromatin immunoprecipitation
(ChIP), that there is a PU.1 binding site within the E2f1 promoter (159), suggesting a
direct mechanism of repression. Staber et al. also went on to elucidate the mechanism
through which PU.1 levels control the cell cycle. Using ChIP sequencing, they found
that PU.1 positively regulated the transcription of cell-cycle inhibitors GFI1 and Cdkn1a
(p21) and negatively regulated the transcription of the cell-cycle activators CDK1, E2F1,
and Cdc25a through direct binding to their promoters and enhancers (141).
In disagreement with the findings of Wontakal et al. and Staber et al., there is
evidence that PU.1 does not function as a repressor (160). While Staber et al. demonstrated that PU.1 binds cell cycle activator promoters and enhancers, they did not actually
demonstrate repression as indicated by chromatin remodeling. Nevertheless, Staber et al.
demonstrated increased cell cycle inhibitor activity with increasing amounts of PU.1, and
decreased cell cycle activator activity (141). This finding suggests PU.1 is able to repress
cell cycle activators, such as E2F1. As mentioned, PU.1 is normally associated with transcriptional activation (160), and it is not known how PU.1 might act as a repressor.
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4.5 Reduced PU.1 levels result in AML
In order to conclusively demonstrate that reduced expression of PU.1 is sufficient to induce AML, transplantation studies were conducted. We injected 1 x 106 spleen
cells from Sfpi1BN/BN mice into NSG recipient mice. All the recipient mice that received
transplanted cells developed AML, and required euthanasia within 6-12 weeks. Recipient
mice had splenomegaly due to an invasion of myeloblastic cells. We also injected 1 x 106
cultured BN cells, into NSG recipients and found the same results as those obtained using the Sfpi1BN/BN splenocytes. Our results confirm what Dr. Tenen’s group found in 2004
(Rosenbauer et al. 2004). Like our lab, Dr. Tenen’s group also characterized the phenotype of mice expressing reduced levels of PU.1, and performed transplantations. Importantly, while both mouse models displayed PU.1 expression at 20% of wild-type levels,
the strategy used to reduce PU.1 expression was different. Dr. Tenen’s group deleted the
entire -14 kb enhancer region of PU.1, while we targeted a coding region. As well, the
length of time it took for mice to develop the disease, differed between studies. Mice
homozygous for this ΔUREneo allele in Rosenbauer et al.’s work developed leukemia in
as early as 3 weeks (47), however it took at least 6 weeks for our mice to become sick.
Furthermore, Dr. Tenen’s group did not propose a mechanism behind the development of
AML in their mice. In another collaborative paper, it was mentioned that HSCs of URE
KO mice progress to leukemia, and it is likely that dysregulated cell cycle regulators
might be involved (141). Our work suggests that PU.1 repression of the cell cycle activator E2F1 is involved in cell cycle exit in the myeloid lineage.
Together, these results indicate that reduced expression of PU.1 is directly responsible for the development of AML and suggest that restoration of PU.1 expression in
individuals with AML could be a therapeutic approach to restore normal myeloid differentiation. The potency and relevance of E2F1 in cell cycle progression and cancer make
it an extremely attractive target in the treatment of AML. The association between PU.1
levels and E2F1 may be manipulated in the future treatment of cancer.
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4.6 Future directions
This project provided insight into the role that PU.1 plays in cell cycle regulation and the development of AML. Nonetheless, certain issues still need to be addressed.
Primarily, the mechanism by which PU.1 regulates E2F1 must be determined. Several experiments are proposed that could illustrate whether the mechanism is indirect or direct.
In order to demonstrate indirect repression, manipulation of miR223 expression is
required. Firstly, it must be established that reintroduction of PU.1 into cultured BN cells
induces miR223 expression. Secondly, it needs to be determined whether transduction
of cultured BN cells with miR223 using a retroviral vector, blocks, or at the very least,
slows proliferation. As well, E2F1 protein levels should be assessed, following transduction with miR223. This is a key experiment because PU.1 expression is not being affected, but the block in proliferation would be attributed to miR223 translational repression
of E2f1 mRNA, indicating an indirect mechanism of repression. However, miR223 may
not be the only form of regulation, or may not play a role at all, and other mechanisms
of indirect repression might exist. Exploring the role of miR223 would still be worthwhile, however, given the large amount of data supporting the indirect pathway involving
miR223.
In order to demonstrate direct repression, ChIP sequencing is required to compile predicted PU.1 binding sites within the regulatory regions of the E2f1 gene. Next,
validation of the predicated PU.1 binding sites would be performed using standard ChIP.
To confirm a repressive function, mutagenesis of the PU.1 binding site(s) within the
E2f1 gene would be conducted, in AML cells. Mutagenesis could be accomplished using
zinc-finger nucleases, which create double-strand breaks in target DNA sequences (161).
If mutagenesis of the PU.1 binding site relieves repression of E2f1 transcriptional activity, the mechanism can be definitively stated as direct. As well, ChIP could be used to
identify chromatin alterations, such as histone deacetylation or methylation, indicative of
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transcriptional inactivation, within the E2f1 promoter, following PU.1 restoration.
We will exploit the inducible system to further assess the effect of E2F1 on BN
cell proliferation/differentiation. For example, following restoration of PU.1 expression
in cultured BN cells, we could overexpress E2F1 to ascertain E2F1’s ability to block cell
cycle arrest. Presumably, overexpression of E2F1 should prevent PU.1 from enabling
cell cycle exit and differentiation of BN cells. As well, knockdown of E2F1 using short
hairpin RNA (shRNA), could be conducted to determine if a dose-dependent reduction in
BN cell proliferation occurs. A significant reduction in E2F1 activity should slow BN cell
growth.
Finally, further elucidating mechanisms by which PU.1 regulates the cell cycle,
aside from E2F1 repression, is necessary. This avenue would permit the discovery of
more therapeutic targets in the treatment of AML. For example, verifying the cell cycle
targets proposed by Staber et al. is one option.
4.7 Summary and conclusions
In this project we sought to explore the mechanism of how PU.1 works to regulate
proliferation and differentiation of myeloid progenitors, and its role in the development
of AML. In doing so, we hypothesized that reduced expression of PU.1 in Sfpi1BN/BN
myeloid cells will result in the development of AML in transplanted mice due to deregulation of the cell cycle, as well as reduced repression of E2F1. The evidence presented in
this monograph supports our hypothesis. We successfully showed how PU.1 expression
at 20% of wild-type levels is sufficient to induce AML in transplanted mice. Furthermore,
we demonstrated that the effect of reduced PU.1 expression is deregulation of the cell
cycle, due to lack of repression of E2F1. Whether PU.1 repression of E2F1 is direct or indirect remains to be confirmed. In conclusion we have shown that normal PU.1 levels are
required to repress E2F1, enabling cell cycle exit and terminal differentiation of myeloid
progenitors.
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